AIDS VACCINE EVALUATION GROUP

MANUSCRIPTS

026 anc

Gorse GJ, Patel GB, Mandava MD, Belshe RB (National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group). Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies. Vaccine. 2000;18:835-849.

In Press

MIL	Jackson S, Prince S, Kulhavy R, Mestecky J. False positivity of enzyme-linked immunosorbent assay for measurement of secretory IgA antibodies directed at HIV type 1 antigens. 2000;In press.
201 core	McElrath MJ, Corey L, Montefiori D, Wolff M, Schwartz D, Keefer M, Belshe R, Graham BS, Matthews T, Wright P, Gorse G, Dolin R, Berman P, Francis D, Duliege AM, Bolognesi D, Stablein D, Ketter N, Fast P, AIDS Vaccine Evaluation Group. A Phase II study of two HIV-1 envelope vaccines comparing their immunogenicity in populations at risk for acquiring HIV-1 infection. 2000;In press, AIDS Res Hum Retroviruses.
029 anc	Sabbaj S, Mulligan MJ, Hsieh RH, Belshe RB, McGhee JR. Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine. 2000;In press, AIDS.

Accepted

104 core

Wright PF, Lambert JS, Gorse GJ, Hsieh RH, McElrath MJ, Weinhold K, Wara DW, Anderson EL, Keefer MC, Jackson S, Wagner LJ, Francis DP, Fast PE, McNamara J, AIDS Vaccine Evaluation Group. Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus infected pregnant women. 1999;Accepted, J Infect Dis.

Submitted

022 core

The AIDS Vaccine Evaluation Group 022 Protocol Team: Corey L, Mulligan M, Goepfert P, Sabbaj S, Clements-Mann ML, Harro C, Schwartz D, Dolin R, Evans T, Keefer M, Belshe R, Gorse G, McElrath J, Graham B, Wright P, Spearman P, Weinhold K, Montefiori D, Greenberg M, Klein M, El Habib R, Excler JL, Duliege AM, Stablein D, Wolff M, Smith C, Grabowsky M, Savarese B, Walker MC. Cellular and humoral immune responses to a canarypox (CP) vaccine containing HIV-1 env, gag-pol in combination with rgp120 (AVEG Protocol 022). 2000;Submitted, J Infect Dis.

022A , 202 anc

Gorse GJ, Patel GB, Mandava MD, Arbuckle JA, Doyle TM, Belshe RB (NIAID AIDS Vaccine Evaluation Group). Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1SF-2 recombinant gp120. 1999;Submitted, Vaccine.

ABSTRACTS / PRESENTATIONS

Accepted

Submitted

MANUSCRIPTS

022 anc	Carruth LM, Greten TF, Murray CE, Castro MG, Crone SN, Pavlat W, Schneck JP, Siliciano RF. An algorithm for evaluating human cytotoxic T lymphocyte responses to candidate AIDS vaccines. AIDS Res Hum Retroviruses. 1999;15:1021-1034.
026 core	Evans TG, Keefer MC, Weinhold KJ, Wolff M, Montefiori D, Gorse GJ, Graham BS, McElrath MJ, Clements-Mann ML, Mulligan MJ, Fast P, Walker MC, Excler JL, Duliege AM, Tartaglia J, NIAID AIDS Vaccine Evaluation Group. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis.1999;180:290-298.
013B core	Gorse GJ, Corey L, Patel GB, Mandava M, Hsieh RH, Matthews TJ, Walker MC, McElrath MJ, Berman PW, Eibl MM, Belshe RB (National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group). HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. AIDS Res Hum Retroviruses. 1999;15:115-132.
006, 009 anc	Gorse GJ, Patel GB, Mandava M, Berman PW, Belshe RB (National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group). MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses. 1999;15:921-930.
mult	Mulligan MJ, Weber J. Human trials of HIV-1 vaccines. AIDS. 1999;13:S105-S112.
nhp	Warren JT, Levinson MA. AIDS preclinical vaccine development: Biennial survey of HIV, SIV and SHIV challenge studies in vaccinated nonhuman primates. J Med Primatol. 1999; 28:249-273

ABSTRACTS / PRESENTATIONS

MANUSCRIPTS

029 core	Belshe RB, Gorse GJ, Mulligan MJ, Evans TG, Keefer MC, Excler JL, Duliege AM, Tartaglia J, Cox WI, McNamara J, Hwang KL, Bradney A, Montefiori D, Weinhold KJ (NIAID AIDS Vaccine Evaluation Group). Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS. 1998;12:2407-2415.
012 core	Clements-Mann ML, Weinhold K, Matthews TJ, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Hsieh RH, Mestecky J, Zolla-Pazner S, Mascola J, Schwartz D, Siliciano R, Corey L, Wright PF, Belshe R, Dolin R, Jackson S, Xu S, Fast P, Walker MC, Stablein D, Excler JL, Tartaglia J, Duliege AM, Sinangil F, Paoletti E, NIAID AIDS Vaccine Evaluation Group. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. J Infect Dis. 1998;177:1230-1246.
010 core	Corey L, McElrath MJ, Weinhold K, Matthews T, Stablein D, Graham B, Keefer M, Schwartz D, Gorse G, AIDS Vaccine Evaluation Group. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. J Infect Dis. 1998;177:301-309.
005, 017 anc	Evans TG, Fitzgerald T, Gibbons DC, Keefer MC, Soucier H, AIDS Vaccine Evaluation Group. Th1/Th2 cytokine responses following HIV-1 immunization in seronegative volunteers. Clin Exp Immunol. 1998;111:243-250.
006 , 009 ext	Francis DP, Gregory T, McElrath MJ, Belshe RB, Gorse GJ, Migasena S, Kitayaporn D, Pitisuttitham P, Matthews T, Schwartz DH, Berman PW. Advancing AIDSVAX™ to Phase 3. Safety, immunogenicity, and plans for Phase 3. AIDS Res Hum Retroviruses. 1998;14(S3):S325-S331.
013A core	Gorse GJ, McElrath MJ, Matthews TJ, Hsieh RH, Belshe RB, Corey L, Frey SE, Kennedy DJ, Walker MC, Eibl MM, National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. Vaccine. 1998;16:493-506.
gen	Graham BS. Science, medicine and the future: infection with HIV-1. Br Med J. 1998;317:1297-1301.
gen	Graham BS, Karzon DT. AIDS vaccine development. Chapter 42. In: Merigan TC, Bartlett JG, Bolognesi D, eds. Textbook of AIDS Medicine. 2nd ed. Williams & Wilkins, Baltimore, MD; 1998:689-724.
401 core	Graham BS, McElrath MJ, Connor RI, Schwartz DH, Gorse GJ, Keefer MC, Mulligan MJ, Matthews TJ, Wolinsky SM, Montefiori DC, Vermund SH, Lambert JS, Corey L, Belshe RB, Dolin R, Wright PF, Korber BT, Wolff MC, Fast PE, AIDS Vaccine Evaluation Group, Correlates of HIV Immune Protection Group. Analysis of intercurrent human immunodeficiency virus type 1 infections in Phase I and II trials of candidate AIDS vaccines. J Infect Dis. 1998;177:310-319.
gen	Tello J, Soong SJ, Hunter B, Meriwether R, Hook EW, Mulligan MJ. HIV vaccine acceptance among heterosexual clients of a sexually transmitted diseases clinic. Am J Med Sci. 1998;315:11-16.

Outside Collaborations

401

Connor RI, Korber BTM, Graham BS, Hahn BH, Ho DD, Walker BD, Neumann AU, Vermund SH, Mestecky J, Jackson S, Fenamore E, Cao Y, Gao F, Kalams S, Kunstman KJ, McDonald D, McWilliams N, Trkola A, Moore JP, Wolinsky SM. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol. 1998:72:1552-1576.

ABSTRACTS / PRESENTATIONS

022 , 026	Castillo RC, Arango-Jaramillo S, Humphrey W, Weinhold K, Schwartz DH. Vaccine induced CTL activity correlates with resistant phenotype in an in vitro challenge system. Poster, 5th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, February 1-5, 1998 [91].
022 /A, 024	Corey L, Weinhold K, Montefiori D, Stablein D. CTL and neutralizing antibody responses with a combination HIV-1 vaccine regimen. Abstract, 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998 [33221].
012B , 022 /A , 026 , 029	Evans T, Corey L, Clements-Mann ML, Weinhold K, Belshe RB, Excler JL, Duliege AM. CD8+ CTL induced in AIDS Vaccine Evaluation Group Phase I trials using canarypox vectors (ALVAC) encoding multiple HIV gene products (vCP125, vCP205, vCP300) given with or without subunit boost. Slide Presentation, 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998 [495].
026 core	Evans TG, Keefer MC, Wolff M, Weinhold K, Excler JL, Duliege AM, Fast P, McElrath MJ, Graham BS, Clements-Mann ML, Mulligan M, Gorse GJ, NIAID AIDS Vaccine Evaluation Group. A canarypox recombinant containing HIV-1 env, gag, pol, and nef genes (vCP300) given with SF-2 rgp120 elicits broad, durable CD8+ CTL in seronegative volunteers. Slide Presentation, 5th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, February 1-5, 1998 [533].
034 core	Fang ZY, Limbach K, Tartaglia J, Spearman P. A canarypox HIV vaccine candidate elicits efficient gag-env pseudovirion formation from human muscle cells. Poster, 36th Annual Meeting, Infectious Diseases Society of America, Denver, Colorado, November 12-15, 1998 [710].
026 anc	Gorse GJ, Patel GB, Mandava MD, Frey SE, Belshe RB (NIAID AIDS Vaccine Evaluation Group). Anti-HIV-1 cytotoxic T cells (CTL) induced by canarypox HIV-1 and SF-2 recombinant gp120 vaccines. Poster Presentation, 36th Annual Meeting, Infectious Diseases Society of America, Denver, Colorado, November 12-15, 1998 [709 Sa].
016B core	Kallas EG, Evans TG, Gorse G, McElrath MJ, Mulligan M, Matthews T, McNamara J, Wolff M, Francis D, AIDS Vaccine Evaluation Group. QS21 is superior to alum as an adjuvant with low dose recombinant MN gp120 for immunization of HIV-1 uninfected volunteers: cellular and humoral responses. Poster, 5th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, February 1-5, 1998 [88].
014C core	Keefer MC, McElrath MJ, Weinhold K, Gorse GJ, Mulligan M, Francis D, Panicali D. A Phase I trial of vaccinia-env/gag/pol (TBC-3B) given by alternative routes, boosted with rgp120. Oral Presentation, 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998 [496].
031 core	Mulligan M, Goepfert P, Corey L, Graham B, Evans T, Weinhold K, Stablein D, Sabbaj S, McElrath J, Hsieh R, Duncan S, Matthews T, Weiner D, Ginsberg R. AVEG 031: Phase I evaluation of a gag-pol facilitated DNA vaccine for HIV-1 prevention. Poster Presentation, 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998 [33216].

Submitted

012B, 022	Ferrari G, Humphrey W, Corr K, Tartaglia J, Clements-Mann ML, Corey LC, Duliege AM, Excler JL, Weinhold KJ, AVEG. Frequency and duration of HIV-1 specific cytolytic reactivities elicited in response to candidate AIDS vaccines. Keystone Symposia–HIV Pathogenesis and Treatment, Park City, Utah, March 13-19, 1998. 1998;Submitted.
mult	Jackson S. Interactions of secretory IgA with HIV-1 gp120: potential pitfalls of anti-HIV ELISA using saliva. 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998. 1998;Submitted.

MANUSCRIPTS

gengen	Crumbo CL, Rybczyk GK, Wagner LJ. Characteristics of volunteer participants in Phase I HIV vaccine trials. Journal of the Association of Nurses in AIDS Care. 1997;8:59-65.
012B, 022	Ferrari G, Humphrey W, McElrath MJ, Excler JL, Duliege AM, Clements ML, Corey LC, Bolognesi DP, Weinhold KJ. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci USA. 1997;94:1396-1401.
gen	Keefer MC, Wolff M, Gorse GJ, Graham BS, Corey L, Clements-Mann ML, Verani-Ketter N, Erb S, Smith CM, Belshe RB, Wagner LJ, McElrath MJ, Schwartz DH, Fast P, NIAID AIDS Vaccine Evaluation Group. Safety profile of Phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses. 1997;13:1163-1177.
002B	Kent SJ, Greenberg PD, Hoffman MC, Akridge RE, McElrath MJ. Antagonism of vaccine-induced HIV-1-specific CD4+ T cells by primary HIV-1 infection. Potential mechanism of vaccine failure. J Immunol. 1997;158:807-815.
104	Lambert JS. Preventive and therapeutic HIV-1 vaccines. In: Cotton D, Watts DH, eds. The Medical Management of AIDS in Women. New York, NY: Wiley-Liss; 1997:415-436.
101	Lambert JS, Viscidi R, Walker MC, Clayman B, Winget M, Wolff M, Schwartz DH, NIAID-sponsored AIDS Vaccine Evaluation Group. Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine. Clin Diagn Lab Immunol. 1997;4:302-308.
gen	Pincus SH, Messer KG, Cole R, Ireland R, VanCott TC, Pinter A, Schwartz DH, Graham BS, Gorse GJ. Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines. J Immunol. 1997;158:3511-3520.
401	Schwartz DH, Laeyendecker OB, Arango-Jaramillo S, Castillo RC, Reynolds MJ. Extensive evaluation of a seronegative participant in an HIV-1 vaccine trial as a result of false-positive PCR. Lancet. 1997;350:256-259.
nhp	Warren JT, Levinson MA. Preclinical AIDS vaccine development: formal survey of global HIV, SIV, and SHIV in vivo challenge studies in vaccinated nonhuman primates. J Med Primatol. 1997;26:63-81.

Outside Collaborations

401	Berman PW, Gray AM, Wrin T, Vennari JC, Eastman DJ, Nakamura GR, Francis DP, Gorse G, Schwartz DH. Genetic and immunology characterization of viruses infecting MN-rgp120-vaccined volunteers. J Infect Dis. 1997;176:384-397.
009, 015, 016, 012A/B anc	Zolla-Pazner S, Alving C, Belshe R, Berman P, Burda S, Chigurupati P, Clements ML, Duliege AM, Excler JL, Hioe C, Kahn J, McElrath MJ, Sharpe S, Sinangil F, Steimer K, Walker MC, Wassef N, Xu S. Neutralization of a clade B primary isolate by sera from HIV-uninfected recipients of candidate AIDS vaccines. J Infect Dis. 1997;175:764-774.

ABSTRACTS / PRESENTATIONS

022 core	Corey L, Weinhold K, Montefiori D, McElrath J, Excler JL, Duliege AM, Stablein D (NIAID AIDS Vaccine Evaluation Group). Combination candidate HIV vaccines using a canarypox vector (vCP205) followed by boosting with gp120SF-2. Abstract, 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
026	Evans TG, Keefer MC, Wolff M, Weinhold K, Excler JL, Duliege A-M, McNamara J, McElrath JM, Graham BJ, Clements ML, Mulligan M, Belshe RB, Tartaglia J, NIAID AIDS Vaccine Evaluation Group. Immunization of HIV-1 non-infected volunteers with a canarypox recombinant containing HIV-1 env, gag, pol, and nef genes (vCP300) given simultaneously or followed by recombinant HIV-1 SF2 gp120. Slide Presentation, 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997 [754].
016B	Evans TG, McElrath MJ, Gorse G, Mulligan M, Keefer M, Matthews T, McNamara J, Fast P, Wolff M, Powell M, Francis D, AIDS Vaccine Evaluation Group. Dose sparing adjuvant effect of QS21 in combination with a recombinant MN gp120 in immunization of HIV-1 uninfected volunteers (AVEG 016B). Abstract, 35th Annual Meeting, Infectious Diseases Society of America, September 1997 [202].
006, 009 anc	Gorse GJ, Patel GB, Mandava M, Berman PW, Belshe RB (NIAID AIDS Vaccine Evaluation Group). Binding antibody against primary HIV-1 isolates induced in recipients of recombinant envelope glycoprotein HIV-1 candidate vaccines (MN/rgp120 and IIIB/rgp120). Poster, 9th Annual Meeting, National Cooperative Vaccine Development Groups, Bethesda, Maryland, May 4-7, 1997 [#107].
022, 026 anc	Sabbaj S, Corey L, Evans T, Keefer M, Excler JL, Duliege AM, Mulligan M, McGhee JR, NIAID AIDS Vaccine Evaluation Group. Cytokine profiles in human PBMC cultures stimulated with HIV antigens in seronegative volunteers immunized with canarypox expressing HIV antigens and boosted with recombinant SF2 gp120. Abstract, 9th Annual Meeting, National Cooperative Vaccine Development Groups, Bethesda, Maryland, May 4-7, 1997 [#110].

Outside Collaborations

gen	Ippolito TM, Francis DP, Migasena S, Pitisuttitham P, Savarese B, Fast P, NIAID AIDS Vaccine Clinical Trials Network. Challenges in assessing the clinical safety of HIV-1 vaccines. Poster Discussion, 11th International Conference on AIDS, Vancouver, Canada, July 7-12, 1996 [We.C.213].

Manuscripts

gen	Clements ML. Candidate HIV vaccines evaluated in clinical trials by the AIDS Vaccine Evaluation Group. Practical Allergy & Immunology. 1996;11:3-10.
gen	Ewell M. Comparing methods for calculating confidence intervals for vaccine efficacy. Stat Med. 1996;15:2379-2392.
011 core	Gorse GJ, Keefer MC, Belshe RB, Matthews TJ, Forrest BD, Hsieh RH, Koff WC, Hanson CV, Dolin R, Weinhold KJ, Frey SE, Ketter N, Fast PE (National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group). A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. J Infect Dis. 1996;173:330-339.
006, 009 anc	Gorse GJ, Patel GB, Newman FK, Belshe RB, Berman PW, Gregory TJ, Matthews TJ (NIAID AIDS Vaccine Evaluation Group). Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. Clin Diagn Lab Immun. 1996;3:378-386.
009 anc	Gorse GJ, Yang EY, Belshe RB, Berman PW (NIAID AIDS Vaccine Evaluation Group). Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. Clin Diagn Lab Immun. 1996;3:769-773.
007 core	Graham BS, Keefer MC, McElrath MJ, Gorse GJ, Schwartz DH, Weinhold K, Matthews TJ, Esterlitz JR, Sinangil F, Fast PE, NIAID AIDS Vaccine Evaluation Group. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. Ann Intern Med. 1996;125:270-279.
005 core	Keefer MC, Graham BS, McElrath MJ, Matthews TJ, Stablein DM, Corey L, Wright PF, Lawrence D, Fast PE, Weinhold K, Hsieh RH, Chernoff D, Dekker C, Dolin R, NIAID AIDS Vaccine Evaluation Group. Safety and immunogenicity of env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. AIDS Res Hum Retroviruses. 1996;12:683-693.
gen	Mestecky J. Impact of mucosal immunity on infection with HIV and design of relevant vaccines. The PRN Notebook. 1996;1:5-9.
gen	Stein RE. Introduction to liability issues in the development of HIV/AIDS drugs and vaccines. Final Report, World Health Organization, Meeting on International Perspectives on Liability Issues in HIV/AIDS Drug and Vaccine Development and Marketing, Geneva, Switzerland, Sept-Oct 1996. [Unpublished]
002 anc	Zhou J, Montefiori DC. Complement-activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35). Virology. 1996;226:13-21.

OUTSIDE COLLABORATIONS

gen

Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Walker MC, Wagner KF, McNeil JG, McCutchan FE, Burke DS (National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group). Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis. 1996;173:340-348.

Abstracts/Presentations

gen	Belshe RB, Bolognesi B, Clements ML, Corey L, Fast P, Graham B, Keefer M, Mestecky J, Mulligan M (NIAID AVEG). Candidate HIV-1 vaccines: what is available for expanded clinical trials? Presentation, 8th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Bethesda, Maryland, February 11-15, 1996:107.
gen	Clements ML. Prevention and treatment of HIV infection. Presentation, American Association for the Advancement of Science, Baltimore, Maryland, February 8-13, 1996.
012, 010, 008 core	Clements ML, Corey L, Weinhold K, Schwartz D, Siliciano R, Matthews T, Hsieh R, Graham B, Keefer M, Gorse G, Zolla-Pazner S, Mascola J, Duliege A, Excler J, Tartaglia J, Paoletti E, Hu SL. HIV immunity induced by priming with canarypox or vaccinia-gp160 recombinants and boosting with rgp120. Presentation, Institute of Human Virology Annual Meeting, Baltimore, Maryland, September 7-13, 1996.
012	Clements ML, Weinhold K, Schwartz D, Siliciano R, Matthews T, Graham B, Keefer M, McElrath J, Gorse G, Hsieh R, Duliege AM, Excler JL, Meigner B, Tartaglia J, Paoletti E. HIV immunity induced by canarypox (ALVAC)-MN gp160, sF2gp120 or both. Presentation, 8th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Bethesda, Maryland, February 11-15, 1996:91.
012 core	Clements ML, Weinhold K, Siliciano R, Schwartz D, Matthews T, Graham B, Keefer M, McElrath J, Gorse G, Hsieh R, Duliege A, Excler J, Meigner B, Tartaglia J, Paoletti E. HIV immunity induced by canarypox (ALVAC)-MN gp160, -SF2 rgp120 or both. Oral Abstract, 11th International Conference on AIDS, Vancouver, Canada, July 7-12, 1996 [Mo.A.281].
022 core	Corey L, Weinhold K, McElrath J, Excler J-L, Duliege AM, Clements ML, Belshe R, Dolin R, Graham B. AVEU 022: Safety and immunogenicity of live recombinant canarypox vector containing the envelope, gag and protease genes of HIV-1 in seronegative adult volunteers. Oral Abstract, 11th International Conference on AIDS, Vancouver, Canada, July 7-12, 1996 [Mo.A.282].
017 anc	Evans TG, Fitzgerald T, Demeter L, Keefer M, Koff W, AIDS Vaccine Clinical Trials Network. Cytokine response to vaccination of HIV seronegative volunteers with a multivalent HIV-1 peptide immunogen. Poster, 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 28-February 1, 1996 [471].
013B core	Gorse GJ, McElrath MJ, Belshe RB, Corey L, Matthews T, Eibl M, Kennedy D, Frey S, Hsieh R, Walker MC. High dose HIV-1 MN recombinant gp160 (rgp160) vaccine induces anti-V3 MN, and IgG1-4 and IgA anti-rgp160 antibodies. Oral Abstract, 11th International Conference on AIDS, Vancouver, Canada, July 7-12, 1996 [Mo.A.153].
013A anc	Gorse GJ, Patel G, Mandava M, Arbuckle JA, Belshe R, Eibl M (NIAID AIDS Vaccine Evaluation Group). T cell memory induced by HIV-1MN recombinant gp160 in healthy volunteers. Poster Presentation, 8th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Bethesda, Maryland, February 11-15, 1996 [64].
gen	Graham B. The basis for clinical evaluation of candidate AIDS vaccines. Presentation, 8th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Bethesda, Maryland, February 11-15, 1996.
gen	Graham BS (NIAID AIDS Vaccine Clinical Trials Network). Phase I/II evaluation of candidate AIDS vaccines. Oral Abstract, 11th International Conference on AIDS, Vancouver, Canada, July 7-12, 1996 [Mo.A.280].
104 core	Lambert JS, Wright P, Fast P, Walker MC, Stablein D, Gorse G, Anderson E, McElrath J, Watts H, Wara D, Landers D, Abramowicz J, Keefer M, Anderson J, Francis D. A Phase I, placebo-controlled, safety and immunogenicity trial of Genentech MN rgp120 HIV-1 vaccine in HIV-infected pregnant women with CD4400. Poster, 3rd Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 28-February 1, 1996 [2].
104 core	Lambert JS, Wright P, Gorse G, Demeter L, McElrath J, Wara D, Keefer M, Anderson J, Fast P, Walker MC, McNamara J, Hsieh R, Francis D. A Phase I, placebo-controlled, safety & immunogenicity trial of Genentech MN rgp120 HIV-1 vaccine in HIV-infected pregnant women with CD4400. Poster Presentation, 8th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Bethesda, Maryland, February 11-15, 1996 [94].
201 core	McElrath MJ, Montefiori DM, Clements ML, Belshe RB, Dolin R, Graham BS, Duliege AM, Francis D, Bolognesi DP, Matthews TJ, Wolff M, Fast P, Corey L. Longitudinal vaccine-induced immunity and risk behavior of study participants of AVEG Phase II Protocol 201. Poster Presentation, 8th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Bethesda, Maryland, February 11-15, 1996 [96].
201 core	McElrath MJ, Montefiori D, Wolff M, Clements M, Gorse G, Keefer M, Graham B, Duliege A-M, Francis D, Matthews T, Fast P, Corey L. Safety, immunity, and risk behavior in HIV-1-uninfected volunteers representing diverse risk populations following recombinant envelope vaccinations: a three-year followup. Oral Abstract, 11th International Conference on AIDS, Vancouver, Canada, July 7-12, 1996 [Mo.A.284].
mult	Nail CD, Shaw GM, Mulligan MJ, AIDS Vaccine Evaluation Group. Sera of HIV-1 vaccinees fail to neutralize both acute seroconverter plasma viruses and CD4-IgG sensitive field isolates. Presentation, 8th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Bethesda, Maryland, February 11-15, 1996:34.
gen	Schwartz DH, Arrango-Jaramillo S, Castillo R, Sridharan G, Clements JL. In vitro resistance to HIV in PBMC cultures from recently infected participants in HIV vaccine trials is CD8 dependent. Poster Abstract, 11th International Conference on AIDS, Vancouver, Canada, July 7-12, 1996 [Mo.A.1117].
gen	Stein RE. Legal and policy issues in vaccine development. Presentation, 8th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Bethesda, Maryland, February 11-15, 1996:104.
gen	Walker MC, McNamara J, Schultz A, Vogel F, Bradac J, Sawyer L, Miller N, Glass M, Savarese B, Wescott S, Flores J, Lawrence D, Grabowsky M, Fast P. Development, preclinical, and clinical testing of candidate AIDS vaccines. Poster Abstract, 11th International Conference on AIDS, Vancouver, Canada, July 7-12, 1996 [Tu.A.2102].

OUTSIDE COLLABORATIONS

401 anc	Berman PW, Gray A, Ashby M, Eastman D, Wrin T, Vennari J-A, Francis D, Gregory T, Fast P, Schwartz D, Gorse G, McElrath MJ. Genetic and immunologic characterization of viruses infecting MN-rgp120 vaccinated volunteers. Oral Abstract, 11th International Conference on AIDS, Vancouver, Canada, July 7-12, 1996 [Mo.A.285].
gen	Duliège A-M, Sinangil F, Walker C, Dekker C, Boggio K, Clements ML, McElrath J, Kahn J, Graham B, Excler JL, McNeil J, Fast P, Steimer K. Recombinant HIV subunit vaccines development: a collaborative effort. 11th International Conference on AIDS, Vancouver, Canada, July 7-12, 1996 [We.B.3376].
gen	Zolla-Pazner S, Berman P, Gregory T, Robert-Guroff M, Natuk R, Sinangil F, Steimer K, NIAID AIDS Vaccine Evaluation Group. Induction of primary isolate-neutralizing antibodies by candidate HIV-1 vaccines. 11th International Conference on AIDS, Vancouver, Canada, July 7-12, 1996 [Mo.A.406].

Manuscripts

gen	Birx DL, Ketter N, Fast P. HIV vaccine development. In: Rich RR, ed. Clinical Immunology: Principles & Practice. St. Louis, MO: Mosby; 1995:764-778.
gen	Clements ML. HIV vaccines. In: Minkoff HL, DeHovitz JA, Duerr A, eds. HIV Infection in Women. New York, NY: Raven Press Ltd.; 1995:33-56.
gen	Dolin R. Human studies in the development of human immunodeficiency virus vaccines. J Infect Dis. 1995;172:1175-1183.
012A anc	Egan MA, Pavlat WA, Tartaglia J, Paoletti E, Weinhold KJ, Clements ML, Siliciano RF. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J Infect Dis. 1995;171:1623-1627.
gen	Fast PE, Johnston MI, Killen JY, AIDS Vaccine Evaluation Group. HIV vaccine clinical trials: experience of the NIAID AIDS Vaccine Evaluation Group. Dixième Colloque des Cent Gardes. 1995;9:293-300.
gen	Fast PE, Sawyer LA, Wescott SL. Clinical considerations in vaccine trials with special reference to candidate HIV vaccines. In: Powell MF, Newman MJ, eds. Vaccine Design: The Subunit and Adjuvant Approach. New York, NY: Plenum Press; 1995:97-134.
004/B anc	Gorse GJ, Patel GB, Newman FK, Mandava M, Belshe RB (NIAID AIDS Vaccine Clinical Trials Network). Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. Vaccine. 1995;13:1170-1179.
004	Gorse GJ, Rogers JH, Perry JE, Newman FK, Frey SE, Patel GB, Belshe RB, NIAID AIDS Vaccine Clinical Trials Network. HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. Vaccine. 1995;13:209-214.
gen	Graham BS, Sawyer LA, Walker MC, Fast PE, Hu SL. Interface between animal models and clinical Phase I trials workshop: conference summary. Conference on Advances in AIDS Vaccine Development-1994. AIDS Res Hum Retroviruses. 1995;11:1305-1306.
gen	Graham BS, Wright PF. Candidate AIDS vaccines. N Engl J Med. 1995;333:1331-1339.
gen	Hammond SA, Johnson RP, Kalams SA, Walker BD, Takiguchi M, Safrit JT, Koup RA, Siliciano RF. An epitope-selective, transporter associated with antigen presentation (TAP)-1/2-independent pathway and a more general TAP-1/2-dependent antigen-processing pathway allow recognition of the HIV-1 envelope glycoprotein by CD8+ CTL. J Immunol. 1995;154:6140-6156.
201 anc	Harrison K, Vlahov D, Jones K, Charron K, Clements ML. Medical eligibility, comprehension of the consent process, and retention of injection drug users recruited for an HIV vaccine trial. J Acquir Immune Defic Syndr. 1995;10:386-390.
gen	Karzon DT. Potential for adverse reactions from HIV vaccines. In: Adverse Reactions to HIV Vaccines: Medical, Ethical, and Legal Issues. U.S. Congress, Office of Technology Assessment; 1995:127-163.
anc	Kent SJ, Corey L, Agy MB, Morton WR, McElrath MJ, Greenberg PD. Cytotoxic and proliferative T cell responses in HIV-1-infected Macaca nemestrina. J Clin Invest. 1995;95:248-256.
gen	Lambert JS. AmFAR Seminar. Passive immunotherapy for prevention and treatment of HIV-1 infection. AIDS Reader. 1995:59-62.
mult	Schwartz DH, Mazumdar A, Winston S, Harkonen S. Utility of various commercially available human immunodeficiency virus (HIV) antibody diagnostic kits for use in conjunction with efficacy trials of HIV-1 vaccines. Clin Diagn Lab Immun. 1995;2:268-271.
gen	Schwartz DH, Sharma UK, Perlman EJ, Blakemore K. Adherence of human immunodeficiency virus-infected lymphocytes to fetal placental cells: a model of maternalfetal transmission. Proc Natl Acad Sci USA. 1995;92:978-982.
gen	Stein RE. Adverse reactions to HIV vaccines: medical, ethical, and legal issues. Final Report. Office of Technology Assessment, Sept 1995.
gen	Walker MC, Fast PE, Graham BS, Belshe R, Dolin R. Phase I/II preventive vaccine trials: conference summary. Conference on Advances in AIDS Vaccine Development-1994. AIDS Res Hum Retroviruses. 1995;11:1279-1285.
nhp	Warren JT, Levinson MA. Fourth annual survey of worldwide HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates. J Med Primatol. 1995;24:150-168.
gen	Wescott S, Savarese B, Smith C. Participation of minority populations in Phase I/II clinical trials of candidate AIDS vaccines: conference summary. Conference on Advances in AIDS Vaccine Development-1994. AIDS Res Hum Retroviruses. 1995;11:1307.

OUTSIDE COLLABORATIONS

002, 003	Perales MA, Schwartz DH, Fabry JA, Lieberman J. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees. J Acquir Immune Defic Syndr. 1995;10:27-35.
003B, 004, 006	VanCott TC, Bethke FR, Burke DS, Redfield RR, Birx DL. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J Immunol. 1995;155:4100-4110.

Abstracts/Presentations

gen	Belshe RB, Bolognesi D, Clements ML, Corey L, Fast P, Graham B, Keefer M, Mestecky J, Mulligan M (NIAID AVEG). Studies on HIV-1 vaccines by the AIDS Vaccine Evaluation Group (AVEG). Published Abstract, [Annual Meeting, Laboratory of Tumor Cell Biology, August 27-September 2, 1995.] AIDS Res Hum Retroviruses 11:S138, 1995 [296].
gen	Belshe RB, Bolognesi D, Clements ML, Corey L, Fast P, Graham B, Keefer M, Mestecky J, Mulligan M, Stablein D (AIDS Vaccine Clinical Trials Group). Progress in HIV-1 vaccine development. Poster, 2nd National Conference on Human Retroviruses and Related Infections, Washington, DC, January 29-February 2, 1995 [517].
012 core	Clements ML, Schwartz D, Siliciano R, Weinhold K, Matthews T, Graham B, Keefer M, McElrath J, Gorse G, Stablein D, Duliege A, Steimer K, Excler JL, Meigner B, Tartaglia J, Paoletti E. HIV immunity induced by canarypox-MN gp160, SF2 gp120, or both. Presentation, 14th Annual Meeting, American Society for Virology, Austin, Texas, July 8-12, 1995.
gen	Clements ML, Stablein D, NIH/NIAID AIDS Vaccine Evaluation Group. The current status of human HIV vaccine trials. Presentation, Advancing a New Agenda for AIDS Research, The Ciba Foundation, London, UK, November 12-14, 1995.
013A core	Gorse GJ, McElrath MJ, Belshe RB, Corey L, Stablein DM, Matthews TJ, Eibl M, Walker MC (NIAID AIDS Vaccine Clinical Trials Network). Evaluation of HIV-1 MN recombinant gp160 candidate vaccine. Poster Presentation, 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, September 17-20, 1995 [I147].
gen	Graham BS. Vaccine-induced cellular immune responses: current findings and new strategies. AIDS Res Hum Retroviruses. 1995;11:S114.
401	Graham BS, McElrath MJ (NIAID-sponsored AIDS Vaccine Clinical Trials Network). HIV infection despite vaccination. Published Abstract, [Annual Meeting, Laboratory of Tumor Cell Biology, August 27-September 2, 1995.] AIDS Res Hum Retroviruses. 1995;11:S131 [266].
017	Keefer MC, Lambert JS, Koff W, Weinhold K, Wolff M, Clements ML, Hosein B, Demeter L, Boyle RW, Dolin R, NIAID AIDS Vaccine Clinical Trials Network. A Phase I study of multivalent HIV-1 peptide vaccine in HIV-1 uninfected subjects. Poster, Annual Meeting, Infectious Diseases Society of America, San Francisco, California, September 16-18, 1995 [403].
gen	McNeil JG, Clements ML, Dina D, Esparza J, Bhamarapravati N. A rational (necessary) philosophy for effective international HIV-1 vaccine development. Presentation, 3rd International Conference on AIDS in Asia and the Pacific, 5th National AIDS Seminar in Thailand, Chiang Mai, Thailand, September 17-21, 1995.
gen	Mestecky J. Mucosal immunology. Presentation, 2nd National Conference on Human Retroviruses and Related Infections, Washington, DC, January 29-February 2, 1995;175.
gen	Mestecky J, Moldoveanu Z, Russell MW, Novak M, Wu HY, Hajishengallis G, Menge AC, Michalek SM. Roles of inductive sites in region-specific secretory immune responses of diverse mucosal tissues. Published Abstract, [Keystone Symposia on Molecular and Cellular Biology, January 16-23, 1995 (J1-010)]. J Cell Biochem. 1995;19A:235.
009 anc	Yang E, Gorse G, Belshe R, Berman P, NIAID AIDS Vaccine Clinical Trials Network. Salivary antibody response to HIV-1 recombinant gp120 (rgp120) vaccine. Poster, 2nd National Conference on Human Retroviruses and Related Infections, Washington, DC, January 29-February 2, 1995 [522].

Manuscripts

gen	Belshe RB, Bolognesi DP, Clements ML, Corey L, Dolin R, Mestecky J, Stablein D, Wright P. HIV infection in vaccinated volunteers. [Letter to the Editor]. JAMA. 1994;272:431.
004 gen	Belshe RB, Clements ML, Keefer MC, Graham BS, Corey L, Sposto R, Wescott S, Lawrence D, NIAID AIDS Vaccine Clinical Trials Group. Interpreting HIV serodiagnostic test results in the 1990s: social risks of HIV vaccine studies in uninfected volunteers. Ann Intern Med. 1994;121:584-589.
009 core	Belshe RB, Graham BS, Keefer MC, Gorse GJ, Wright P, Dolin R, Matthews T, Weinhold K, Bolognesi DP, Sposto R, Stablein DM, Twadell T, Berman PW, Gregory T, Izu AE, Walker MC, Fast P (NIAID AIDS Vaccine Clinical Trials Network). Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA. 1994;272:475-480.
006 anc	Berman PW, Eastman DJ, Wilkes DM, Nakamura GR, Gregory TJ, Schwartz D, Gorse G, Belshe R, Clements ML, Byrn RA. Comparison of the immune response to recombinant gp120 in humans and chimpanzees. AIDS. 1994;8:591-601.
gen	Dolin R, Keefer MC. Vaccines for HIV-1 Infection. In: Mandell G, Bennett J, Dolin R, eds. Principles and Practice of Infectious Diseases. 4th ed. New York, NY: Churchill-Livingstone; 1994:1294-1305.
gen	Fast PE. Phase I and II trials of candidate HIV-1 vaccines: current status and future directions. Neuvième Colloque des Cent Gardes. 1994;293-299.
gen	Fast PE, Mathieson BJ, Schultz AM. Efficacy trials of AIDS vaccines: how science can inform ethics. [Guest editorial]. Curr Opin Immunol. 1994;6:691-697.
gen	Fast PE, Walker MC, Verani-Ketter N, Wescott SL, Vogel FR, Schultz AM, NIAID AIDS Vaccine Clinical Trials Network. Evaluation of candidate HIV-1 prophylactic vaccines in Phase I/II trials. Huitième Colloque des Cent Gardes. 1994;8:271-279.
gen	Golding H, D'Souza MP, Bradac J, Mathieson B, Fast P. Meeting Report. Neutralization of HIV-1. AIDS Res Hum Retroviruses. 1994;10:633-643.
gen	Gorse GJ. Phase I/II trials of preventive HIV vaccine candidates. Dose and schedule: summary. AIDS Res Hum Retroviruses. 1994;10:S141-S143.
002+boost anc	Gorse GJ, Frey SE, Patel G, Newman FK, Belshe RB, NIAID AIDS Vaccine Clinical Trials Network. Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. Vaccine. 1994;12:912-918.
004B core	Gorse GJ, Schwartz DH, Graham BS, Matthews TJ, Stablein DM, Frey SE, Belshe RB, Clements ML, Wright PF, Eibl M, Fast PE, NIAID AIDS Vaccine Clinical Trials Network. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immunol. 1994;98:178-184.
mult	Graham BS. Serological responses to candidate AIDS vaccines. AIDS Res Hum Retroviruses. 1994;10:S145-S148.
002 core	Graham BS, Gorse GJ, Schwartz DH, Keefer MC, McElrath MJ, Matthews TJ, Wright PF, Belshe RB, Clements ML, Dolin R, Corey L, Bolognesi DP, Stablein DM, Esterlitz JR, Hu SL, Smith GE, National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. J Infect Dis. 1994;170:782-786.
anc	Johnson RP, Hammond SA, Trocha A, Siliciano RF, Walker BD. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine. J Virol. 1994;68:3145-3153.
gen	Karzon DT. Preventive vaccines. In: Broder S, Merigan T, Bolognesi D, eds. Textbook of AIDS Medicine. Baltimore, MD: Williams & Wilkins; 1994:667-692.
mult	Keefer MC, Belshe R, Graham B, McElrath J, Clements ML, Sposto R, Fast P, NIAID AIDS Vaccine Clinical Trials Network. Phase I/II trials of preventive HIV vaccine candidates. Safety profile of HIV vaccination: first 1000 volunteers of AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses. 1994;10:S139-S140.
003A/B core	Keefer MC, Graham BS, Belshe RB, Schwartz D, Corey L, Bolognesi DP, Stablein DM, Montefiori DC, McElrath MJ, Clements ML, Gorse GJ, Wright PF, Matthews TJ, Smith GE, Lawrence D, Dolin R, AIDS Vaccine Clinical Trials Network. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. AIDS Res Hum Retroviruses. 1994;10:1713-1723.
nhp	Kent SJ, Stallard V, Corey L, Hu SL, Morton WR, Gritz L, Panicali DL, Greenberg PD. Analysis of cytotoxic T lymphocyte responses to SIV proteins in SIV-infected macaques using antigen-specific stimulation with recombinant vaccinia and fowl poxviruses. AIDS Res Hum Retroviruses. 1994;10:551-560.
gen	Kutteh WH, Mestecky J. Secretory immunity in the female reproductive tract. Amer J Reprod Immunol. 1994;31:40-46.
gen	Lubaki MN, Egan MA, Siliciano RF, Weinhold KJ, Bollinger RC. A novel method for detection and ex vivo expansion of HIV type 1-specific cytolytic T lymphocytes. AIDS Res Hum Retroviruses. 1994;10:1427-1431.
gen	McElrath MJ, Corey L. Current status of vaccines for HIV. In: Pizzo PH, Wilfert CM, eds. Pediatric AIDS: The Challenge of HIV Infection in Infants, Children and Adolescents. Baltimore, MD: Williams & Wilkins; 1994:869-887.
002	McElrath MJ, Corey L, Berger D, Hoffman MC, Klucking S, Dragavon J, Peterson E, Greenberg PD. Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: analysis of the durability of responses and effect of repeated boosting. J Infect Dis. 1994;169:41-47.
002/B	McElrath MJ, Corey L, Greenberg PD. Cytotoxic T cells in adults and children. Evaluation of cytotoxic T cell responses to candidate HIV-1 vaccines in HIV-1-uninfected individuals. AIDS Res Hum Retroviruses. 1994;10:S69-S72.
002B	McElrath MJ, Corey L, Greenberg PD, Matthews TJ, Montefiori DC, Rowen L, Hood L, Mullins JI. Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen. Proc Natl Acad Sci USA. 1994;93:3972-3977.
mult	McElrath MJ, Hoffman M, Klucking S, Corey L, Greenberg PD. HIV-infected macrophages as efficient stimulator cells for detection of cytotoxic T cell responses to HIV in seronegative and seropositive vaccine recipients. AIDS Res Hum Retroviruses. 1994;10:541-549.
002/B	McElrath MJ, Rabin M, Hoffman M, Klucking S, Garcia JV, Greenberg PD. Evaluation of human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T-lymphocyte responses utilizing B-lymphoblastoid cell lines transduced with the CD4 gene and infected with HIV-1. J Virol. 1994;68:5074-5083.
gen	McNamara JG, Rogers M, Goldenthal K, Jackson JB, Rossi P, Fenton T, Fast PE. Conference on Advances in AIDS Vaccine Development-1993. Report of Perinatal Intervention Working Group. AIDS Res Hum Retroviruses. 1994;10:S161-S164.
gen	Mestecky J, Jackson S. Reassessment of the impact of mucosal immunity in infection with the human immunodeficiency virus (HIV) and design of relevant vaccines. J Clin Immunol. 1994;14:259-272.
gen	Mestecky J, Kutteh WH, Jackson S. Mucosal immunity in the female genital tract: relevance to vaccination efforts against the human immunodeficiency virus. AIDS Res Hum Retroviruses. 1994;10:S11-S20.
gen	Mestecky J, Moldoveanu Z, Novak M, Compans RW. Mucosal immunity and strategies for novel microbial vaccines. Acta Paediatr Jpn. 1994;36:537-544.
gen	Mestecky J, Moldoveanu Z, Novak M, Huang WQ, Gilley RM, Staas JK, Schafer D, Compans RW. Biodegradable microspheres for the delivery of oral vaccines. J Controlled Release. 1994;28:131-141.
gen	Mestecky J, Walker MC, Mathieson BJ, Walker BD. Conference on Advances in AIDS Vaccine Development-1993. Summary: Mucosal Immunity Workshop. AIDS Res Hum Retroviruses. 1994;10:S165-S170.
anc	Miskovsky EP, Liu AY, Pavlat W, Viveen R, Stanhope PE, Finzi D, Fox III WM, Hruban RH, Podack ER, Siliciano RF. Studies of the mechanism of cytolysis by HIV-1-specific CD4+ human CTL clones induced by candidate AIDS vaccines. J Immunol. 1994;153:2787-2799.
103	Mohamed OA, Ashley R, Goldstein J, McElrath J, Dalessio J, Corey L. Detection of rectal antibodies to HIV-1 by a sensitive chemiluminescent Western Blot immunodetection method. J Acquir Immune Defic Syndr. 1994;7:375-380.
002	Montefiori DC, Graham BS, Zhou JY, Zhou JT, Ahearn JM, National Institutes of Health AIDS Vaccine Clinical Trials Network. Binding of human immunodeficiency virus type 1 to the C3b/C4b receptor CR1 (CD35) and red blood cells in the presence of envelope-specific antibodies and complement. J Infect Dis. 1994;170:429-432.
gen	Olson RR, Reuter JJ, McNicholl J, Alber C, Klohe E, Callahan K, Siliciano RF, Karr RW. Acidic residues in the DR chain third hypervariable region are required for stimulation of a DR(,1*0402)-restricted T-cell clone. Hum Immunol. 1994;41:193-200.
gen	Schwartz D, Sharma U, Busch M, Weinhold K, Matthews T, Lieberman J, Birx D, Farzedagen H, Margolick J, Quinn T, Davis B, Bagasra O, Pomerantz R, Viscidi R. Absence of recoverable infectious virus and unique immune responses in an asymptomatic HIV+ long-term survivor. AIDS Res Hum Retroviruses. 1994;10:1703-1711.
gen	Schwartz DH. Potential pitfalls on the road to an effective HIV vaccine. Immunol Today. 1994;15:54-57.
002, 003B, 006 anc	Schwartz DH, Cosentino LM, Shirai A, Conover J, Daniel S, Klinman DM. Lack of correlation between the number of circulating B cells and the concentration of serum antibodies reactive with the HIV-1 envelope glycoprotein. J Acquir Immune Defic Syndr. 1994;7:447-453.
gen	Sheppard H, Bridges SH, Mathieson BJ, Walker MC, Weinhold K. Conference on Advances in AIDS Vaccine Development-1993. Summary: Correlates of HIV Immunity Working Group. AIDS Res Hum Retroviruses. 1994;10:S171-S176.
gen	Siliciano RF. CD4-positive T cell responses to HIV-1 infection. Chapter 14. In: Karn J, ed. HIV: A Practical Approach. Oxford, UK: Oxford University Press; 1994:221-238.
gen	Stein RE. Vaccine liability and participant compensation incentives in HIV vaccine trials. AIDS Res Hum Retroviruses. 1994;10:S297-S300.
gen	Walker MC, Fast PE. Clinical trials of candidate AIDS vaccines. AIDS. 1994;8:S213-S236.
gen	Walker MC, Walker BD, Mestecky J, Mathieson BJ. Conference on Advances in AIDS Vaccine Development-1993. Summary: Cytotoxic T-Cell Immunity Workshop. AIDS Res Hum Retroviruses. 1994;10:S177-S179.
nhp	Warren JT, Dolatshahi M. Annual updated survey of worldwide HIV, SIV and SHIV challenge studies in vaccinated nonhuman primates. J Med Primatol. 1994;23:184-225.

Abstracts/Presentations

gen	Charron K, Harris M, Jones K, Reynolds MJ, Zimmerman E, McCourt B. The use of interactive media for recruitment and education of AIDS vaccine volunteers. Poster, 7th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Reston, Virginia, November 6-10, 1994;127 [1].
gen	Clements ML. Clinical care for the patient with HIV infection. Presentation, Johns Hopkins University AIDS Service Course, Baltimore, Maryland, April 7, 1994.
gen	Clements ML. Design of safety and efficacy trials for AIDS vaccines. Presentation, Harvard School of Public Health, Boston, Massachusetts, May 18, 1994.
gen	Clements ML. Historical perspectives on HIV vaccine development. Presentation, HIV Vaccine Working Group, Reston, Virginia, April 21, 1994.
gen	Clements ML. Overview of AIDS vaccine development and evaluation. Presentation, Federation of American Societies for Experimental Biology Symposium, Anaheim, California, April 24, 1994.
gen	Clements ML. Workshop: preparation for HIV vaccine evaluation. Presentation, Ugandan Minister of Health and Ugandan AIDS Commission, Kampala, Uganda, March 9-11, 1994.
gen	Clements ML. Workshop: update on AIDS vaccine development. Presentation, United States Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand, January 13-21, 1994.
gen	Clements ML. Workshop: update on AIDS vaccine development and evaluation. Presentation, Keystone Symposia on Molecular and Cellular Biology: Prevention and Treatment of AIDS, Hilton Head Island, South Carolina, January 23-30, 1994.
012A	Clements ML, Eagan M, Schwartz D, Weinhold K, Graham B, Keefer M, McElrath J, Gorse G, Tartaglia J, Duliege AM, Excler JL, Walker MC. Humoral and cell-mediated immune responses of HIV-1 seronegative volunteers following prime-boost with canarypox (ALVAC)-MN gp160 alone or with SF2 gp120-MF59 subunit vaccine. Presentation, 7th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Reston, Virginia, November 6-10, 1994:93.
012A	Egan MA, Pavlat W, Weinhold K, Paoletti E, Tartaglia J, Clements M, Siliciano R. Cytotoxic T lymphocyte responses to a prime-boost AIDS vaccine regimen (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 seronegative adult volunteers. Poster, 7th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Reston, Virginia, November 6-10, 1994:131 [5].
gen	Fast P, Walker MC, Wescott SL, Schultz AM, AIDS Vaccine Clinical Trials Network. Phase I/II trials of candidate HIV-1 vaccines. Presentation, Annual Meeting of the Laboratory of Tumor Cell Biology, Rockville, Maryland, September 25-October 1, 1994 [206].
gen	Fast PE, Walker MC, Ketter N, Schultz AM, AIDS Vaccine Clinical Trials Network. Evaluation of candidate HIV-1 vaccines in Phase I/II trials. Presentation, Keystone Symposia on Molecular and Cellular Biology, Hilton Head Island, South Carolina, January 23-30, 1994 [J021].
009	Francis DP, Fast P, Harkonen S, McElrath MJ, Belshe R, Berman P, Gregory T, AIDS Vaccine Evaluation Group. MN rgp120 (Genentech) vaccine safe and immunogenic - But will it protect humans? Presentation, 10th International Conference on AIDS, International Conference on STD, Yokohama, Japan, August 7-12, 1994 [314A].
011 core	Gorse GJ, Keefer M, Weinhold K, Matthews T, Frey S, Stablein D, Potts B, Koff W, NIAID AIDS Vaccine Clinical Trials Network. Evaluation of HIV-1 MN V3 octameric peptide vaccine. Presentation, 7th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Reston, Virginia, November 6-10, 1994:94.
011 core	Gorse GJ, Keefer M, Weinhold K, Matthews T, Stablein D, Potts B, Forrest B, NIAID AIDS Vaccine Clinical Trials Network (AVEG). Phase I study of HIV-1 MN V3 octameric peptide vaccine. Poster, 10th International Conference on AIDS, International Conference on STD, Yokohama, Japan, August 7-12, 1994 [PA0375].
009 anc	Gorse GJ, Patel GB, Newman FK, Belshe RB, Berman PW, Matthews TJ, NIAID AIDS Vaccine Clinical Trials Network. Vaccine induced antibodies to native HIV-1 gp120 measured by flow cytometry. Poster, 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida, October 4-7, 1994 [I136].
gen	Graham BS. Animal model/clinical trials interface. Presentation, 7th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Reston, Virginia, November 6-10, 1994.
gen	Graham BS. Preventive vaccines for AIDS: hopes, hurdles, and choices. Presentation, 10th International Society of African Scientists Technical Conference, AIDS in Africa and the Caribbean: Enabling Communities to Find Solutions, McLean, Virginia, September 1994.
401	Graham BS. Review of subjects infected with HIV-1 despite vaccination with candidate AIDS vaccines. Presentation, 7th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Reston, Virginia, November 6-10, 1994.
gen	Graham BS (NIAID AIDS Vaccine Clinical Trials Network). Vaccine-induced cellular immune responses: current findings and new strategies. Presentation, Annual Meeting of the Laboratory of Tumor Cell Biology, Rockville, Maryland, September 25-October 1, 1994 [203].
101	Lambert J, Clements ML, Viscidi R, Schwartz D, Clayman B, AIDS Vaccine Evaluation Group. Measurement of antibody to HIV-1 gp160 in mucosal specimens of asymptomatic seropositive volunteers immunized with parenterally administered IMMUNOAG rgp160 IIIB. Poster, 7th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Reston, Virginia, November 6-10, 1994:129 [3].
104	Lambert JS, Wright P, Fast P, Walker MC, Stablein D, Gorse G, Anderson E, McElrath J, Watts H, Wara D, Landers D, Abramowicz J, Keefer M, Anderson J, Francis D (AIDS Vaccine Evaluation Group). A Phase I, placebo-controlled, safety and immunogenicity trial of Genentech MN rgp120 HIV-1 vaccine in HIV-infected pregnant women with CD4400. Poster, 7th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Reston, Virginia, November 6-10, 1994:128 [2].
gen	McElrath MJ. Cytotoxic T cell responses in volunteers participating in HIV vaccine trials. Presentation, Meeting of Investigators in HIV- and SIV-Specific CTL, Annecy, France, May 1994.
015, 016/A/B	McElrath MJ. Use of rgp120 with multiple adjuvants: AVEG Protocols 015 and 016. Oral Presentation, 7th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Reston, Virginia, November 6-10, 1994
201	McElrath MJ, Corey L, Clements ML, Belshe R, Keefer M, Graham B, Fast P, Duliege AM, Francis D, NIAID AIDS Vaccine Clinical Trials Network. A Phase II HIV vaccine trial in seronegative volunteers: expanded safety and immunogenicity evaluation of two recombinant gp120 vaccines. Presentation, Keystone Symposia on Molecular and Cellular Biology: Prevention and Treatment of AIDS, Hilton Head Island, South Carolina, January 23-30, 1994 [J412].
201	McElrath MJ, Corey L, Clements ML, Belshe R, Keefer M, Graham B, Fast P, Matthews T, Duliege AM, Francis D, NIAID AVEG. A Phase II HIV vaccine trial in seronegative subjects: safety, immunogenicity, and future directions. Presentation, 10th International Conference on AIDS, International Conference on STD, Yokohama, Japan, August 7-12, 1994 [317A].
gen	Mestecky J. Relevance of mucosal immunity to the development of vaccines against the human immunodeficiency virus. Published Abstract [2nd International Conference on Engineered Vaccines for Cancer and AIDS, San Francisco, California, March 3-5, 1994]. Cancer Biotherapy. 1994;10:82-83.
012A	Schwartz DH, Sridharan G, Clements ML, Lambert J, Arango-Jaramillo S. PBMC resistance to in vitro challenge with HIV-1MN after ALVAC-MN gp160 priming and SF2 gp120 boosting (AVEG Trial 012A): a potential system for vaccine evaluation. Presentation, Poster, 7th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Reston, Virginia, November 6-10, 1994:53;132 [6].
gen	Stein R. Confidentiality and reporting requirements: what's a site to do? Presentation, 7th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Reston, Virginia, November 6-10, 1994.
201	Wagner L. Preventing and mitigating discrimination among AVEG Protocol 201 volunteers. Presentation, 7th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Reston, Virginia, November 6-10, 1994.
gen	Walker MC, Schultz AM, Fast PE, Mathieson BJ, Bradac J, Vogel FR, Glass M, Wescott S, Miller N. HIV-1 vaccine development and clinical trials. Presentation, 10th International Conference on AIDS, International Conference on STD, Yokohama, Japan, August 7-12, 1994 [313A].
nhp	Warren JT, Dolatshahi M. Update of international HIV-1, SIV, SHIV, and HIV-2 challenge/protection studies in vaccinated nonhuman primates. Poster, 12th Annual Symposium on Nonhuman Primate Models for AIDS, Boston, Massachusetts, October 12-15, 1994 [118].
104	Wright PF. Active immunization of HIV-infected women during pregnancy. Presentation, 7th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Reston, Virginia, November 6-10, 1994.

OUTSIDE COLLABORATIONS

mult	Parekh B, Phillips S, George JR, AIDS Vaccine Clinical Trials Network. Evaluation of commercial HIV diagnostic assays to discriminate serological response of candidate AIDS vaccine recipients from that of HIV-infected individuals. AIDS Res Hum Retroviruses. 1994;10:S34.

Manuscripts

004 core	Belshe RB, Clements ML, Dolin R, Graham BS, McElrath J, Gorse GJ, Schwartz D, Keefer MC, Wright P, Corey L, Bolognesi DP, Matthews TJ, Stablein DM, O'Brien FS, Eibl M, Dorner F, Koff W, National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. J Infect Dis. 1993;168:1387-1395.
002, 003 anc	Bollinger RC, Quinn TC, Liu AY, Stanhope PE, Hammond SA, Viveen R, Clements ML, Siliciano RF. Cytokines from vaccine-induced HIV-1 specific cytotoxic T lymphocytes: effects on viral replication. AIDS Res Hum Retroviruses. 1993;9:1067-1077.
gen	Callahan KM, Rowell JF, Soloski MJ, Machamer CE, Siliciano RF. HIV-1 envelope protein is expressed on the surface of infected cells before its processing and presentation to class II-restricted T lymphocytes. J Immunol. 1993;151:2928-2942.
002B core	Cooney EL, McElrath MJ, Corey L, Hu SL, Collier AC, Arditti D, Hoffman M, Coombs RW, Smith GE, Greenberg PD. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci USA. 1993;90:1882-1886.
002 anc, 003/B	De Santis C, Robbioni P, Longhi R, Lopalco L, Siccardi AG, Beretta A, Roberts NJ Jr. Cross-reactive response to human immunodeficiency virus type 1 (HIV-1) gp120 and HLA class I heavy chains induced by receipt of HIV-1-derived envelope vaccines. J Infect Dis. 1993;168:1396-1403.
002 anc	El-Daher N, Keefer MC, Reichman RC, Dolin R, Roberts NJ Jr. Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines. J Infect Dis. 1993;168:306-313.
101	Funkhouser A, Clements ML, Slome S, Clayman B, Viscidi R. Antibodies to recombinant gp160 in mucosal secretions and sera of persons infected with HIV-1 and seronegative vaccine recipients. AIDS Res Hum Retroviruses. 1993;9:627-632.
002 core	Graham BS, Matthews TJ, Belshe RB, Clements ML, Dolin R, Wright PF, Gorse GJ, Schwartz DH, Keefer MC, Bolognesi DP, Corey L, Stablein DM, Esterlitz JR, Hu SL, Smith GE, Fast PE, Koff WC, NIAID AIDS Vaccine Clinical Trials Network. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. J Infect Dis. 1993;167:533-537.
gen	Hammond SA, Bollinger RC, Tobery TW, Siliciano RF. Letter: Transporter-independent processing of HIV-1 envelope protein for recognition by CD8+ T cells. Nature. 1993;364:158-161.
002	Hesselton RM, Koup RA, Cromwell MA, Graham BS, Johns M, Sullivan JL. Human peripheral blood xenografts in the SCID mouse: Characterization of immunologic reconstitution. J Infect Dis. 1993;168:630-640.
gen	Lambert JS, McNamara JG, Rodriguez EM, Fast PE. Summary of the perinatal intervention working group. AIDS Res Hum Retroviruses. 1993;9:S53-S54.
002	Montefiori DC, Graham BS, Zhou JT, Zhou JY, Bucco RA, Schwartz DH, Cavacini LA, Posner MR, NIH-NIAID AIDS Vaccine Clinical Trials Network. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. J Clin Invest. 1993;92:840-847.
002B	Mosier DE, Gulizia RJ, MacIsaac PD, Corey L, Greenberg PD. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160. Proc Natl Acad Sci USA. 1993;90:2443-2447.
anc	Pincus SH, Messer KG, Schwartz DH, Lewis GK, Graham BS, Blattner WA, Fisher G. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. J Clin Invest. 1993;91:1987-1996.
gen	Ray S, Siliciano R, Bollinger R. Immunization and immunotherapy for human immunodeficiency virus type 1 (HIV-1) infection: a brief review. Venereology. 1993;6:93-94.
006 core	Schwartz DH, Gorse G, Clements ML, Belshe R, Izu A, Duliege AM, Berman P, Twaddell T, Stablein D, Sposto R, Siliciano R, Matthews T. Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine. Lancet. 1993;342:69-73.
gen	Siliciano RF. CD4+ T cell epitopes in HIV-1 proteins. In: Norrby E, ed. Immunochemistry of AIDS. Vol. 56. Basel, Switzerland: Karger; 1993:127-149.
004 anc	Stanhope PE, Clements ML, Siliciano RF. Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine. J Infect Dis. 1993;168:92-100.
002, 003B anc	Stanhope PE, Liu AY, Pavlat W, Pitha PM, Clements ML, Siliciano RF. An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes. J Immunol. 1993;150:4672-4686.
gen	Stein RE. Insurance and liability issues in the development of an HIV vaccine. Food, Drug, Cosmetic and Medical Device Law Digest. 1993;10:80-83.
nhp	Warren JT, Dolatshahi M. First updated and revised survey of worldwide HIV and SIV vaccine challenge studies in nonhuman primates: Progress in first and second order studies. J Med Primatol. 1993;22:203-235.

Abstracts/Presentations

009 core	Belshe R, Keefer M, Graham B, Matthews T, Twaddell T, Fast P, NIAID AIDS Vaccine Evaluation Network. Safety and immunogenicity of HIV-1 (MN or combination MN/IIIB) rgp120 vaccines in low risk volunteers. Abstract, 9th International Conference on AIDS/4th STD World Congress, Berlin, Germany, June 6-11, 1993 [WS-B27-1].
009	Belshe RB, Keefer M, Graham B, Matthews T, Twaddell T, Berman P, Fast P, NIAID AIDS Vaccine Evaluation Network. Cross-reactive neutralizing antibody induced by (MN or MN+IIIB) rgp120/HIV-1 vaccines in low risk volunteers. Presentation, 1st National Conference on Human Retroviruses and Related Infections, Washington, D.C., December 12-16, 1993 [49].
009 core	Belshe RB, Keefer M, Graham B, Matthews T, Twaddell T, Berman P, Fast P, NIAID AIDS Vaccine Evaluation Network. Neutralizing antibody induced by (MN or combination MN/IIIB) rgp120/HIV-1 vaccines in low risk volunteers. Presentation, 6th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Alexandria, Virginia, October 30-November 4, 1993.
006	Berman P, Matthews T, Eastman D, Nakamura G, Murthy K, Schwartz D, et al. Comparison of the immune response to recombinant gp120 in man and chimpanzees. Poster, 9th International Conference on AIDS/4th STD World Congress, Berlin, Germany, June 6-11, 1993 [PO-B27-2135].
gen	Clements ML. Update on AIDS vaccines. Presentation, JHU SOM Conjoint Clinic, December 18, 1993.
103	Corey L, McElrath J, Keefer M, Paxton W, Sposto R, Chernoff D, NIAID AVEG. A Phase I HIV-1 vaccine trial in asymptomatic HIV-infected individuals using env 2-3 in MF-59 with or without MTP-PE. Poster, 9th International Conference on AIDS/4th STD World Congress, Berlin, Germany, June 6-11, 1993 [PO-B28-2152].
103	Corey L, McElrath MJ, Keefer M, Dolin R, Chernoff D, Greenberg PD, Coombs R, Steimer K, Sposto R, NIAID AIDS Vaccine Clinical Trials Network, Chiron Corporation. An AVEG Phase I randomized, blinded, controlled trial in asymptomatic HIV-infected subjects using env 2-3 in MF-59 with or without MTP-PE. Presentation, 6th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Alexandria, Virginia, October 30-November 4, 1993.
012A	Egan MA, Weinhold K, Paoletti E, Tartaglia J, Clements ML, Pavlat W, Siliciano RF. Cytotoxic T lymphocyte responses to recombinant canarypox-gp160 MN (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 uninfected adult volunteers. Presentation, 6th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Alexandria, Virginia, October 30-November 4, 1993.
004B anc	Gorse G, Patel G, Belshe R, Mandava M, Morris M, NIAID AIDS Vaccine Clinical Trials Network. Detection of cellular immunity following accelerated rgp160 vaccination regimens in low risk volunteers. Poster, 9th International Conference on AIDS/4th STD World Congress, Berlin, Germany, June 6-11, 1993 [PO-B27-2130].
004/B anc	Gorse G, Patel G, Mandava M, Belshe R, NIAID AIDS Vaccine Clinical Trials Network. Cellular immune responses to T-cell epitopes of HIV-1 envelope glycoprotein after vaccination with recombinant gp160 (rgp160). Presentation, 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, October 17-20, 1993 [1135].
004B core	Gorse G, Schwartz D, Graham B, Bolognesi D, Belshe R, Eibl M. Safety and immunogenicity of rgp160 in accelerated dose schedules. Abstract, 9th International Conference on AIDS/4th STD World Congress, Berlin, Germany, June 6-11, 1993 [WS-B27-4].
gen	Gorse GJ, Schwartz DH, Keefer MC, McElrath J, Graham B, Belshe R, Clements ML, Dolin R, Corey L, Wright P, Frey SE, Eibl M, Fast P, Stablein D, NIAID AIDS Vaccine Clinical Trials Network. Summary of vaccinia-expressed rgp160 subunit vaccine dosing and scheduling studies. Presentation, 6th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Alexandria, Virginia, October 30-November 4, 1993.
004/A/B	Gorse GJ, Schwartz DH, Keefer MC, McElrath J, Graham B, Belshe R, Clements ML, Dolin R, Corey L, Wright P, Frey SE, Eibl M, Fast P, Stablein D, NIAID AIDS Vaccine Clinical Trials Network. Vaccinia-expressed rgp160 subunit vaccine dosing and scheduling studies. Poster, 1st National Conference on Human Retroviruses and Related Infections, Washington, D.C., December 12-16, 1993 [101].
007	Graham B, Keefer M, McElrath J, Matthews T, Schwartz D, Gorse G, Sposto R, Chernoff D, NIAID AIDS Vaccine Clinical Trials Network. Phase I trial of native HIV-1SF-2 rgp120 candidate vaccine. Poster, 9th International Conference on AIDS/4th STD World Congress, Berlin, Germany, June 6-11, 1993 [PO-A29-0692].
gen	Graham BS. Phase I/II trials of preventive HIV vaccine candidates: Functional versus binding antibodies. Slide Presentation, 6th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Alexandria, Virginia, October 30-November 4, 1993.
007	Graham BS, Keefer M, McElrath MJ, Schwartz D, Gorse G, Matthews T, Sposto R, Chernoff D, NIAID AVEG. Cross-reactive neutralizing (NT) antibody (AB) induced by native HIV-1SF-2 rgp120. Presentation, 6th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Alexandria, Virginia, October 30-November 4, 1993.
007	Graham BS, Keefer M, McElrath MJ, Schwartz D, Gorse G, Matthews T, Sposto R, Chernoff D, NIAID AVEG. Cross-reactive neutralizing (NT) antibody (AB) induced by native HIV-1SF-2 rgp120 candidate vaccine. Presentation, 1st National Conference on Human Retroviruses and Related Infections, Washington, D.C., December 12-16, 1993 [48].
005A/B/C core	Keefer M, Graham B, McElrath J, Matthews T, Chernoff D, Dolin R, et al. Phase I trial of an HIV-1 vaccine candidate, env 2-3, in combination with MTP-PE/MF59. Poster, 9th International Conference on AIDS/4th STD World Congress, Berlin, Germany, June 6-11, 1993 [PO-A29-0708].
005A/B/C core	Keefer M, Graham B, McElrath J, Matthews T, Sposto R, Fast P, Chernoff D, Dolin R, AIDS Vaccine Clinical Trials Network. Phase I trial of an HIV-1 vaccine candidate, env 2-3, in combination with MTP-PE/MF59. Poster, 6th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Alexandria, Virginia, October 30-November 4, 1993 [112].
005A/B/C core	Keefer M, McElrath J, Graham B, Matthews T, Chernoff D, Dolin R, AIDS Vaccine Clinical Trials Network. Safety and immunogenicity of a preventive HIV-1 vaccine candidate, env 2-3, in combination with MTP-PE/MF59. Poster, 1st National Conference on Human Retroviruses and Related Infections, Washington, D.C., December 12-16, 1993 [103].
gen	Kent SJ, Corey L, McElrath J, Morton W, Greenberg P. Cytotoxic T lymphocyte responses in HIV-1 infected Macaca nemestrina. Poster, 6th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Alexandria, Virginia, October 30-November 4, 1993 [78].
201	Klucking S, Corey L, Berger D, Stacey H, Dithmer-Schreck D, Burke L, Corey L, Greenberg P, McElrath J. Human T cell responses after receipt of recombinant HIV envelope vaccines in a Phase II trial. Poster, 6th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Alexandria, Virginia, October 30-November 4, 1993 [110].
gen	Lambert JS. Organization and activities of the AIDS Vaccine Evaluation Group (AVEG). Presentation, 6th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Alexandria, Virginia, October 30-November 4, 1993.
mult	Matthews T, McDanal C, Greenwell T, Streilein A, Davison D, Ruland M, Bolognesi D, Bradac J, Walker MC. Serological reactivity from HIV-1 vaccine recipients participating in the AIDS Vaccine Clinical Trials Network. Presentation, 6th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Alexandria, Virginia, October 30-November 4, 1993.
002B	McElrath J, Greenberg P, Hoffman M, Klucking S, Rabin M, Weinhold K, NIAID AVEG. Analysis of cytotoxic T lymphocyte responses in HIV-1 seronegative recipients of recombinant vaccinia vectors encoding HIV-1 gp160 and envelope subunit protein vaccines. Poster, 9th International Conference on AIDS/4th STD World Congress, Berlin, Germany, June 6-11, 1993 [PO-A29-0693].
103	McElrath J, Keefer M, Greenberg P, Sposto R, Chernoff D, Steimer K, NIAID AVEG. Evaluation of a nonglycosylated yeast-derived envelope vaccine on HIV-1-specific immunity in a randomized, blinded, controlled HIV-1 seropositive trial. Poster, 9th International Conference on AIDS/4th STD World Congress, Berlin, Germany, June 6-11, 1993 [PO-A28-0670].
201	McElrath MJ, Corey L, Clements ML, Belshe R, Keefer M, Graham B, Sposto R, Fast P, NIAID AIDS Vaccine Clinical Trials Network, Chiron Corporation, Genentech Inc. Expanded safety and immunogenicity trial of recombinant gp120 vaccines among seronegative volunteers (AVEG Protocol 201). Presentation, 6th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Alexandria, Virginia, October 30-November 4, 1993.
mult	McElrath MJ, Corey L, Rabin M, Hoffman M, Klucking S, Greenberg PD. CTL responses in HIV-1 uninfected volunteers participating in Phase I HIV-1 vaccine trials. J Cell Biochem. 1993;S17E:82 [Q538].
002/B	McElrath MJ, Greenberg PD, Corey L. Cytotoxic T cell responses to candidate HIV-1 vaccines in HIV-1 uninfected individuals. Poster, 1st National Conference on Human Retroviruses and Related Infections, Washington, D.C., December 12-16, 1993 [104].
gen	McElrath MJ, Greenberg PD, Corey L. Evaluation of cytotoxic T cell responses to candidate HIV-1 vaccines in HIV-1 uninfected individuals. Presentation, 6th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Alexandria, Virginia, October 30-November 4, 1993.
103	McElrath MJ, Keefer M, Paxton WB, Chernoff D, Sinangil F, Steimer K, Sposto R, Coombs R, Dolin R, Greenberg P, Corey L, NIAID AVEG. A Phase I randomized, blinded, controlled vaccine trial in asymptomatic HIV-infected individuals using env 2-3 in MF-59 with or without MTP-PE. Abstract, Annual Meeting, Infectious Diseases Society of America, New Orleans, Louisiana, October 16-18, 1993 [200].
002	Montefiori DC, Zhou JY, Zhou JT, Ahearn JM, NIH AIDS Vaccine Clinical Trials Network. Binding of HIV-1 to the C3b/C4b receptor, CR1 (CD35), in the presence of complement and antibodies from infected individuals and gp160-vaccinated volunteers. Abstract, Annual Meeting of the Laboratory of Tumor Cell Biology, Bethesda, Maryland, August 22-28, 1993.
gen	Musey L, Hoffman M, Kent S, Schacker T, Coombs R, Corey L, McElrath MJ. Evaluation of cytotoxic T cell responses in early HIV infection. Slide Presentation, 1st National Conference on Human Retroviruses and Related Infections, Washington, D.C., December 12-16, 1993 [41].
002 anc	Perales MA, Schwartz DH, Fabry JA, Lieberman J. A vaccinia-gp160 based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees. Poster, 6th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Alexandria, Virginia, October 30-November 4, 1993 [109].
004 anc	Perry J, Gorse G, Rogers J, Newman F, Belshe R, NIAID AIDS Vaccine Clinical Trials Network. Salivary antibody responses to recombinant HIV-1 gp160 vaccine. Poster, 9th International Conference on AIDS/4th STD World Congress, Berlin, Germany, June 6-11, 1993 [PO-B27-2132].
012A	Salmon D, Excler JL, Plotkin S, Pialoux G, Rivière Y, Autran B, Glückman JC, Matthews T, AGIS Group, ANRS. A prime-boost approach to HIV preventive vaccines using a MN-gp160 recombinant canarypox virus and envelope subunits (rgp160, V3 peptide). Presentation, 6th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Alexandria, Virginia, October 30-November 4, 1993.
gen	Schultz AM, Fast PE, Mathieson BJ, Bradac J, Vogel FR, Walker MC, et al. Status of AIDS vaccine development and testing. Poster, 9th International Conference on AIDS/4th STD World Congress, Berlin, Germany, June 6-11, 1993 [PO-A29-0707].
006	Schwartz D, Clements ML, Belshe R, Gorse G, Izu A, Matthews T, NIAID AIDS Vaccine Evaluation Group. Antibody responses to neutralizing domains of gp120 in HIV() vaccinees boosted with homologous or heterologous rgp120. Poster, 9th International Conference on AIDS/4th STD World Congress, Berlin, Germany, June 6-11, 1993 [PO-A29-0690].
101	Schwartz D, Clements ML, Belshe R, Gorse G, Wright P, Graham B. Interim results of rgp160 vaccine trial in HIV+ volunteers. Poster, 9th International Conference on AIDS/4th STD World Congress, Berlin, Germany, June 6-11, 1993 [PO-A28-0668].
006	Schwartz D, Clements ML, Gorse G, Belshe R, Izu A, Twaddell T, Matthews T, Posner M, Deaconess NE, Sposto R, Stablein D (AIDS Vaccine Evaluation Group). Neutralization profile after sequential immunization with IIIB-rgp120 followed by MN-rgp120. Poster, 6th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Alexandria, Virginia, October 30-November 4, 1993 [108].
gen	Siliciano RF, Hammond SA, Bollinger RC. Recognition of HIV-1 envelope protein by CD8+ cytolytic T lymphocytes involves a novel antigen processing pathway: implications for vaccine design. Poster, 6th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Alexandria, Virginia, October 30-November 4, 1993 [52].
anc	Siliciano RF, Hammond SA, Bollinger RC, Stanhope PE, Quinn TC, Schwartz D, Clements ML. Comparative clonal analysis of HIV-1-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with HIV-1 vaccines. AIDS Res Hum Retroviruses. 1993;9:S46.
gen	Stein R. Vaccine liability and participant compensation in trials: incentives or disincentives to vaccine trials? Presentation, 6th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Alexandria, Virginia, October 30-November 4, 1993.
gen	Wagner LJ, Harris V, Rybczyk GK, Braeuner M, Parti N, Battle W, Graham BS. Joining the solution: an AIDS vaccine recruitment video targeting minority populations. Poster, 6th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Alexandria, Virginia, October 30-November 4, 1993 [113].
nhp	Warren JT, Dolatshahi M. Update of worldwide HIV and SIV challenge/protection studies in vaccinated nonhuman primates: progress in first and second order studies. Poster, 9th International Conference on AIDS/4th STD World Congress, Berlin, Germany, June 6-11, 1993 [PO-A30-0720].
mult	Weinhold KJ, Rathbun KT, Place CA, Ferrari G, Bolognesi DP. Cytotoxic T-lymphocyte reactivities among HIV-1 vaccine recipients in the AIDS Vaccine Evaluation Network. Presentation, 6th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Alexandria, Virginia, October 30-November 4, 1993.

OUTSIDE COLLABORATIONS

mult

Mascola J, Weislow O, Snyder S, Belay S, Yeager M, McCutchan F, McNeil J, Burke D, Walker MC (AIDS Vaccine Clinical Trials Network). Neutralizing antibody activity in sera from human immunodeficiency virus type-1 vaccine recipients from the AIDS Vaccine Clinical Trials Network. Presentation, 6th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Alexandria, Virginia, October 30-November 4, 1993.

Manuscripts

003 anc	Gorse GJ, Belshe RB, Newman FK, Frey SE, NIAID AIDS Vaccine Clinical Trials Network. Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant gp160. Vaccine. 1992;10:383-388.
003 anc	Gorse GJ, Frey SE, Newman FK, Belshe RB, AIDS Vaccine Clinical Trials Network. Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. J Clin Microbiol. 1992;30:2606-2612.
002	Graham BS. Clinical trials of AIDS vaccines in seronegative volunteers: vectors and combinations. AIDS Res Hum Retroviruses. 1992;8:1327-1328.
002 core	Graham BS, Belshe RB, Clements ML, Dolin R, Corey L, Wright PF, Gorse GJ, Midthun K, Keefer MC, Roberts NJ Jr, Schwartz DH, Agosti JM, Fernie BF, Stablein DM, Montefiori DC, Lambert JS, Hu SL, Esterlitz JR, Lawrence DN, Koff WC, AIDS Vaccine Clinical Trials Network. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. J Infect Dis. 1992;166:244-252.
002	Hammond SA, Bollinger RC, Stanhope PE, Quinn TC, Schwartz D, Clements ML, Siliciano RF. Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines. J Exp Med. 1992;176:1531-1542.
gen	Karzon DT, Bolognesi DP, Koff WC. Development of a vaccine for the prevention of AIDS, a critical appraisal. Vaccine. 1992;10:1039-1052.
101	Liu AY, Miskovsky EP, Stanhope PE, Siliciano RF. Production of transmembrane and secreted forms of tumor necrosis factor (TNF)- by HIV-1-specific CD4+ cytolytic T lymphocyte clones: Evidence for a TNF--independent cytolytic mechanism. J Immunol. 1992;148:3789-3798.
002	Montefiori DC, Graham BS, Kliks S, Wright PF, NIAID AIDS Vaccine Clinical Trials Network. Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. J Clin Immunol. 1992;12:429-439.
002	Montefiori DC, Zhou J, Shaff DI. CD4-independent binding of HIV-1 to the B lymphocyte receptor CR2 (CD21) in the presence of complement and antibody. Clin Exper Immunol. 1992;90:383-389.
gen	Siliciano RF, Bollinger RC, Callahan KM, Hammond SA, Liu AY, Miskovsky EP, Rowell JF, Stanhope PE. Clonal analysis of T-cell responses to the HIV-1 envelope proteins in AIDS vaccine recipients. AIDS Res Hum Retroviruses. 1992;8:1349-1352.
gen	Stein RE. The development of an HIV vaccine: Legal and policy aspects. In: Vaccine Research and Developments, Koff WC, Six HR, eds. New York, NY: Marcel Dekker, Inc.; 1992:223-245.
104	Ukwu HN, Graham BS, Lambert JS, Wright PF. Perinatal transmission of human immunodeficiency virus-1 infection and maternal immunization strategies for prevention. Obstet Gynecol. 1992;80:458-468.
nhp	Warren JT, Dolatshahi M. Worldwide survey of AIDS vaccine challenge studies in nonhuman primates: vaccines associated with active and passive immune protection from live virus challenge. J Med Primatol. 1992;21:139-186.

OUTSIDE COLLABORATIONS

003	Keay S, Tacket CO, Murphy JR, Handwerger BS. Anti-CD4 anti-idiotype antibodies in volunteers immunized with rgp160 of HIV-1 or infected with HIV-1. AIDS Res Hum Retroviruses. 1992;8:1091-1098.

Abstracts/Presentations

004 core	Belshe RB, Clements ML, Dolin R, Corey L, Graham B, Bolognesi D, Stablein D, Eibl M, Fast P, NIAID AIDS Vaccine Clinical Trials Network. Safety and immunogenicity of fully glycosylated rgp160 IIIB vaccine in low risk volunteers. Poster, 8th International Conference on AIDS/3rd STD World Congress, Amsterdam, The Netherlands, July 19-24, 1992 [PoA 2432].
004 core	Belshe RB, Clements ML, Dolin R, Corey L, Graham B, Bolognesi D, Stablein D, Eibl M, Fast P, NIAID AIDS Vaccine Clinical Trials Network. Safety and immunogenicity of fully glycosylated rgp160 IIIB vaccine in low risk volunteers. Presentation, 5th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Chantilly, Virginia, August 30-September 3, 1992.
003	Callahan KM, Rowell J, Hammond SA, Stanhope PE, Pavlat W, Siliciano RF. Recognition of HIV-1 infected cells by CD4+ T cells: analysis of antigen processing mechanisms. Abstract, Presentation, Annual Meeting of the Laboratory of Tumor Cell Biology, Washington, D.C., August 9-14, 1992.
gen	Clements ML. Overview of HIV vaccines. Presentation, 2nd International Formosa AIDS Conference, Taipei, Taiwan, May 15-17, 1992.
gen	Clements ML. Overview of HIV vaccines. Published Abstract (National Foundation for Infectious Diseases), 5th National Forum on AIDS, Hepatitis, and Other Blood-Borne Diseases, Atlanta, Georgia, March 29-April 1, 1992.
006	Clements ML, Belshe R, Duliege AM, Schwartz D, Gorse G, Izu A, Ammann A, NIAID-sponsored AIDS Vaccine Clinical Trials Network. Safety and immunogenicity of IIIB rgp120/HIV-1 vaccine in seronegative volunteers. Presentation, 8th International Conference on AIDS/3rd STD World Congress, Amsterdam, The Netherlands, July 19-24, 1992 [MoB 0026].
gen	Clements ML, Graham B, Belshe R, Dolin R, Corey L, Fast P, Stablein D, Siliciano R, Bolognesi D, Wright P, Gorse G, Keefer M, Schwartz D, McElrath J, Matthews T. Immunological responses in HIV-seronegative volunteers to live recombinant and subunit HIV-1 envelope vaccines. Slide Presentation, Annual Meeting of the Laboratory of Tumor Cell Biology, Washington, DC, August 9-14, 1992.
anc	Cosentino M, Daniel S, Schwartz D, Klinman D. A comparison between the number of IgG -gp160 secreting cells in peripheral blood and the level of serum IgG -gp160 from gp160 immunized volunteers. Poster, 5th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Chantilly, Virginia, August 30-September 3, 1992 [73].
005A/B/C core	Dolin R, Corey L, Graham B, Wright P, McElrath J, Keefer M, Matthews T, Stablein D, Dekker C. Safety and immunogenicity of an HIV vaccine candidate, env 2-3, in combination with MTP-PE/MF59. Presentation, 5th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Chantilly, Virginia, August 30-September 3, 1992.
005A/B/C core	Dolin R, Corey L, Graham B, Wright P, McElrath J, Keefer M, Matthews T, Stablein D, Dekker C, AIDS Vaccine Clinical Trials Network. Safety and immunogenicity of an HIV vaccine candidate, env 2-3, in combination with MTP-PE/MF59. Poster, 8th International Conference on AIDS/3rd STD World Congress, Amsterdam, The Netherlands, July 19-24, 1992 [PoA 2226].
002 anc	El-Daher N, Keefer MC, Reichman RC, Dolin R, Roberts NJ Jr. HIV-1 rgp160-specific proliferative responses, interferon- production, and cytotoxic T lymphocyte activity of human mononuclear leukocytes from vaccine recipients. Presentation, 11th Annual Meeting, American Society for Virology, Ithaca, New York, July 11-15, 1992.
002 anc	El-Daher N, Keefer MC, Reichman RC, Dolin R, Roberts NJ Jr, NIAID AIDS Vaccine Clinical Trials Network. Persisting HIV-1 gp160-specific human T lymphocyte responses after receipt of vaccinia recombinant and purified subunit HIV-derived envelope vaccines. Abstract, Poster, 5th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Chantilly, Virginia, August 30-September 3, 1992 [72].
004	Gorse G, Belshe R, AIDS Vaccine Clinical Trials Network. Lymphocyte proliferation following vaccination with fully glycosylated gp160. Poster, 8th International Conference on AIDS/3rd STD World Congress, Amsterdam, The Netherlands, July 19-24, 1992 [PoB 3038].
002+boost	Gorse GJ, Frey SE, Patel G, Newman FK, Belshe RB, NIAID AIDS Vaccine Clinical Trials Network. Antibodies to native and recombinant HIV-1 gp160 following a combination HIV-1LAV vaccine regimen. Presentation, Annual Meeting, Infectious Diseases Society of America, Anaheim, California, October 10-12, 1992 [59].
gen	Graham BS. Overview of clinical trials evaluating candidate HIV-1 vaccines. Presentation, 5th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Chantilly, Virginia, August 30-September 3, 1992.
002	Graham BS, Belshe R, Clements M, Dolin R, Corey L, Matthews T, Esterlitz J, Fast P, NIAID AIDS Vaccine Clinical Trials Network. Determinants of antibody (AB) response in volunteers primed with vac-env and boosted with rgp160. Slide Presentation, 8th International Conference on AIDS/3rd STD World Congress, Amsterdam, The Netherlands, July 19-24, 1992 [MoA0013].
003A/B core	Keefer M, Belshe R, Clements M, Graham B, Corey L, Bolognesi D, Stablein D, Fast P, Montefiori D, Smith G, Dolin R. Safety and immunogenicity of a baculovirus derived HIV-1 IIIB recombinant gp160 vaccine (Vaxsyn®) in humans. Presentation, 5th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Chantilly, Virginia, August 30-September 3, 1992.
003A/B core	Keefer M, Belshe R, Clements M, Graham B, Corey L, Bolognesi D, Stablein D, Koff W, Montefiori D, Smith G, Dolin R. Safety and immunogenicity of a baculovirus-derived HIV-1 IIIB recombinant gp160 vaccine (Vaxsyn®). Poster, 8th International Conference on AIDS/3rd STD World Congress, Amsterdam, The Netherlands, July 19-24, 1992 [PoA 2228].
002/B	McElrath J, Greenberg P, Corey L. Combination HIV vaccine trial in seropositive individuals: role of additional subunit boosts in immune response. 5th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Chantilly, Virginia, August 30-September 3, 1992.
002B	McElrath J, Petersen E, Dragavon J, Berger D, Hoffman M, Klucking S, Greenberg P, Corey L. Combination prime-boost approach to HIV vaccination in seronegative individuals: enhanced immunity with additional subunit gp160 protein boosting. Abstract, 8th International Conference on AIDS/3rd STD World Congress, Amsterdam, The Netherlands, July 19-24, 1992 [MoB 0027].
mult	McElrath MJ. Human HIV vaccine trials. Presentation, Keystone Symposia on AIDS: HIV Pathogenesis, Keystone, Colorado, April 1, 1992.
006	Schwartz D, Clements ML, Berman P, Duliege AM, Twadell T, Ammann A, Belshe R, Gorse G, Matthews T, Bolognesi D, Fast P, Sposto R, Stablein D (NIH NIAID AVEG). Safety and immunogenicity of Genentech HIV IIIB rgp120/HIV-1. Presentation, 5th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Chantilly, Virginia, August 30-September 3, 1992.
anc	Siliciano RF, Callahan K, Liu AY, Hammond S, Stanhope PE. The role of HIV-1 specific T cells in the pathogenesis and prevention of AIDS. Presentation, Keystone Symposia on AIDS: HIV Pathogenesis, Keystone, Colorado, April 1, 1992 [Q 017].
gen	Stein R. Insurance and liability issues in AIDS vaccine development. Presentation, 5th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Chantilly, Virginia, August 30-September 3, 1992.
nhp	Warren JT. Survey of AIDS vaccine challenge studies in nonhuman primates: Vaccines associated with active and passive immune protection from live virus challenge. Presentation, 5th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Chantilly, Virginia, August 30-September 3, 1992.
nhp	Warren JT. The impetus for tracking nonhuman primate AIDS vaccine/live virus challenge studies. J Med Primatol. 1992;21:138.
nhp	Warren JT, Dolatshahi M. Update of HIV and SIV challenge/protection studies in vaccinated nonhuman primates: progress in first and second order studies. Abstract, 10th Annual Symposium on Nonhuman Primate Models for AIDS, San Juan, Puerto Rico, November 17-20, 1992 [131A].

Manuscripts

003 anc	Clerici M, Berzofsky JA, Shearer GM, Tacket CO. Exposure to human immunodeficiency virus type 1-specific T helper cell responses before detection of infection by polymerase chain reaction and serum antibodies. J Infect Dis. 1991;164:178-182.
003 anc	Clerici M, Tacket CO, Via CS, Lucey DR, Muluk SC, Zajac RA, Boswell RN, Berzofsky JA, Shearer GM. Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection. Eur J Immunol. 1991;21:1345-1349.
002	Cooney EL, Collier AC, Greenberg PD, Coombs RW, Zarling J, Arditti DE, Hoffman MC, Hu SL, Corey L. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet. 1991;337:567-572.
003 core	Dolin R, Graham BS, Greenberg SB, Tacket CO, Belshe RB, Midthun K, Clements ML, Gorse GJ, Horgan BW, Atmar RL, Karzon DT, Bonnez W, Fernie BF, Montefiori DC, Stablein DM, Smith GE, Koff WC, NIAID AIDS Vaccine Clinical Trials Network. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. Ann Intern Med. 1991;114:119-127.
003 anc	Hammond SA, Obah E, Stanhope P, Monell CR, Strand M, Robbins FM, Bias WB, Karr RW, Koenig S, Siliciano RF. Characterization of a conserved T cell epitope in HIV-1 gp41 recognized by vaccine-induced human cytolytic T cells. J Immunol. 1991;146:1470-1477.
003 anc	Keefer MC, Bonnez W, Roberts NJ Jr, Dolin R, Reichman RC. Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients. J Infect Dis. 1991;163:448-453.
gen	Kotloff KL, Tacket CO, Clemens JD, Wasserman SS, Cowan JE, Bridwell MW, Quinn TC. Assessment of the prevalence and risk factors for human immunodeficiency virus type 1 (HIV-1) infection among college students using three survey methods. Am J Epidemiol. 1991;133:2-8.
gen	Schwartz DH. Scientific Correspondence: AIDS response. Nature. 1991;354:439.
gen	Steinhoff MC, Auerbach BS, Nelson KE, Vlahov D, Becker RL, Graham NMH, Schwartz DH, Lucas AH, Chaisson RE. Antibody responses to Haemophilus influenza type B vaccines in men with human immunodeficiency virus infection. N Engl J Med. 1991;325:1837-1842.
gen	Westblom TU, Belshe RB, Gorse GJ. Current progress in HIV vaccines. Mo Med. 1991;88:762-765.

OUTSIDE COLLABORATIONS

gen	Berkower I, Murphy D, Smith CC, Smith GE. A predominant group-specific neutralizing epitope of human immunodeficiency virus type 1 maps to residues 342 to 511 of the envelope glycoprotein gp120. J Virol. 1991;65:5983-5990.
gen	Montefiori DC, Hirsch VM, Johnson PR. Scientific Correspondence: AIDS response. Nature. 1991;354:439-440.

Abstracts/Presentations

gen	Berry CD, Graham BS, Perez-Perez GI, Coombs RW, Montefiori DC, Chiang CS, Pandey JP, Grove TH, Ellison III RT, Blaser MJ. Anti-fusion and neutralizing activity, anti-CD4, and IgG allotypes in sera of HIV-infected patients. Abstract, 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 29-October 2, 1991 [632].
003	Bollinger R, Liu A, Hammond S, Stanhope P, Clements ML, Quinn T, Siliciano R. HIV-specific cytolytic T lymphocytes from seronegative HIV vaccine recipients up-regulate HIV replication. 4th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Marco Island, Florida, October 15-19, 1991.
002+boost anc	Frey SE, Gorse GJ, Newman FK, Belshe RB, NIAID AIDS Vaccine Clinical Trials Network. Anti-gp160 enzyme linked immunosorbent assay antibody responses to a combination human immunodeficiency virus vaccine regimen. Clin Res. 1991;39:727A.
003 anc	Gorse GJ, Belshe RB, Tsai CC, Frey SE, Newman FK, NIAID AIDS Vaccine Clinical Trials Network. Analysis of anti-HIV antibody responses by flow cytometric indirect immunofluorescence assay (FIFA) following rgp160 immunization. Poster, 7th International Conference on AIDS, Florence, Italy, June 16-21, 1991 [W.A.1324].
003 anc	Gorse GJ, Frey SE, Newman FK, Tsai CC, Belshe RB, NIAID AIDS Vaccine Clinical Trials Network. Comparison of anti-HIV antibody responses to rgp160 immunization by flow cytometry and enzyme immunoassays. Poster, 4th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Marco Island, Florida, October 15-19, 1991 [11].
002	Graham BS, Belshe R, Clements ML, Dolin R, Corey L, Matthews T, Bolognesi D, Stablein D, Wright PF, Hu SL, Smith G, Koff W (NIAID AIDS Vaccine Clinical Trials Network). HIV-gp160 recombinant vaccinia vaccination of vaccinia-naive adults followed by rgp160 booster immunization. Presentation, 4th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Marco Island, Florida, October 15-19, 1991.
002	Graham BS, Belshe R, Clements ML, Dolin R, Fernie B, Stablein D, Wright P, Koff W, NIAID AIDS Vaccine Clinical Trials Network. HIV-gp160 recombinant vaccinia vaccination of vaccinia-naive adults followed by rgp160 booster immunization. Slide Presentation, 7th International Conference on AIDS, Florence, Italy, June 16-21, 1991.
003	Mosier DE, Gulizia RJ, MacIsaac P, Mathieson BJ, Smith G, Hu SL, Corey L, Greenberg P. Evaluation of gp160 vaccinees in the hu-PBL-SCID mouse model. Presentation, Poster, 4th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Marco Island, Florida, October 15-19, 1991 [12].
003	Mosier DE, Gulizia RJ, MacIsaac PD, Torbett BE, Hesselton R, Koup R, Sullivan JL, Wright P, Graham B, Dolin R, Belshe R, Mathieson B, Smith G, Volvovitz F, Hu SL, Corey L, Greenberg P. Evaluation of HIV-1 vaccines in hu-PBL-SCID mice. Presentation, 7th International Conference on AIDS, Florence, Italy, June 16-21, 1991 [TH.A.10].
nhp	Schultz AM, Warren J. Surveillance of AIDS vaccine studies in non-human primates. Poster, 7th International Conference on AIDS, Florence, Italy, June 16-21, 1991 [M.A.1337].
gen	Seaman WT, Belshe RB, Fenger TW, AIDS Vaccine Clinical Trials Network. Functional expression of human immunodeficiency virus env gene product in CD4+ HELA cells. Poster, 4th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Marco Island, Florida, October 15-19, 1991 [59].
mult	Siliciano RF, Hammond SC, Liu A, Miskovsky E, Stanhope PE, Clements ML. Clonal analysis of CTL reponses in AIDS vaccine recipients. Presentation, 4th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Marco Island, Florida, October 15-19, 1991.
gen	Weinhold KJ, Tartataglia J, Paoletti E, Graham B, Schwartz D, McElrath J, Roberts N, Gorse G (AVEG Immunologists). Specific activation strategies for amplification of low CTL signals. Presentation, 4th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Marco Island, Florida, October 15-19, 1991.

OUTSIDE COLLABORATIONS

003 anc	Haubrich R, Takeda A, Koff W, Smith G, Ennis FA. Lack of FcR mediated immune enhancement in sera from recipients of a rgp160 experimental HIV vaccine. Poster, 7th International Conference on AIDS, Florence, Italy, June 16-21, 1991 [M.A.1327].
mult	Kliks SC, Wu WW, Levy JA. V3 epitopes can mediate antibody neutralization and enhancement of HIV-1 infection. Abstract, 7th International Conference on AIDS, Florence, Italy, June 16-21, 1991 [M.A.73].
gen	Pincus SH, Messer K. Humoral immune responses to homologous envelope peptides in vaccinees and lab workers infected with HIV. Abstract, Poster, 4th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Marco Island, Florida, October 15-19, 1991 [10].

Manuscripts

003 anc	Archibald DW, Hebert CA, Sun D, Tacket CO. Salivary antibodies to human immunodeficiency virus type 1 in a Phase I AIDS vaccine trial. J Acquir Immune Defic Syndr. 1990;3:954-958.
gen	Ellerbeck E, Clements ML. AIDS vaccines. In: Mandell GL, Douglas RG, Bennett JE, eds. Principles and Practice of Infectious Diseases, Update #7. New York, NY: Churchill-Livingstone; 1990:1-15.
gen	Graham BS, Karzon DT. Development of an AIDS vaccine: biological and ethical challenges. Infect Dis Clin North Am. 1990;4:223-243.
002	Graham BS, Rowland JM, Modliszewski A, Montefiori DC. Antifusion activity in sera from persons infected with human immunodeficiency virus type 1. J Clin Microbiol. 1990;28:2608-2611.
gen	Koff WC, Wescott SL, Hoth DF. Clinical trials of AIDS vaccines. In: Putney SD, Bolognesi DP, eds. AIDS Vaccine Research and Clinical Trials. New York, NY: Marcel Dekker, Inc.; 1990:425-438.
mult	Midthun K, Garrison L, Clements ML, Farzadegan H, Fernie B, Quinn T, NIAID AIDS Vaccine Clinical Trials Network. Frequency of indeterminate Western Blot tests in healthy adults at low risk for human immunodeficiency virus infection. J Infect Dis. 1990;162:1379-1382.
gen	Montefiori DC, Murphey-Corb M, Desrosiers RC, Daniel MD. Complement-mediated, infection-enhancing antibodies in plasma from vaccinated macaques before and after inoculation with live simian immunodeficiency virus. J Virol. 1990;64:5223-5225.
003 anc	Orentas RJ, Hildreth JEK, Obah E, Polydefkis M, Smith GE, Clements ML, Siliciano RF. Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine. Science. 1990;248:1234-1237.
003 anc	Polydefkis M, Koenig S, Flexner C, Obah E, Gebo K, Chakrabarti S, Earl PL, Moss B, Siliciano RF. Anchor sequence-dependent endogenous processing of human immunodeficiency virus 1 envelope glycoprotein gp160 for CD4+ T cell recognition. J Exp Med. 1990;171:875-887.
gen	Schindzielorz AH, Belshe RB, Mufson MA. Occurrence, characteristics, and patterns of HIV-1 and HIV-2 Western Blot indeterminate sera in low risk populations in West Virginia and pre-AIDS Africa. Am J Trop Med Hyg. 1990;42:460-464.
gen	Stablein DM. Challenges of HIV vaccine development. Stat Med, 1990;9:1425-1431.
003	Tacket CO, Baqar S, Munoz C, Murphy JR. Lymphoproliferative responses to mitogens and HIV-1 envelope glycoprotein among volunteers vaccinated with recombinant gp160. AIDS Res Hum Retroviruses. 1990;6:535-542.
gen	Tacket CO, Edelman R. Ethical issues involving volunteers in AIDS vaccine trials. J Infect Dis. 1990;161:356.
003	Viscidi R, Ellerbeck E, Garrison L, Midthun K, Clements ML, Clayman B, Fernie B, Smith G, NIAID AIDS Vaccine Clinical Trials Network. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. AIDS Res Hum Retroviruses. 1990;6:1251-1256.
002, 003 anc	Westblom TU, Belshe RB, Gorse GJ, Anderson EL, Berry CF, NIAID AIDS Vaccine Clinical Trials Network. Characteristics of a population volunteering for human immunodeficiency virus immunization. Int J STD AIDS. 1990;1:126-128.

Abstracts/Presentations

003 anc	Clerici M, Tacket CO, Via CS, Berzofsky JA, Shearer GM. HIV-specific B and T lymphocyte functions in uninfected human volunteers immunized with HIV recombinant gp160. Poster, 6th International Conference on AIDS, San Francisco, California, June 20-24, 1990;1:203 [Th.A.332].
002B	Cooney EL, Corey L, Hu SL, Collier A, Arditti D, Hoffman M, Smith G, Steimer K, Greenberg P. Enhanced immunogenicity in humans of an HIV subunit vaccine regimen employing priming with a vaccinia gp160 recombinant virus (vac/env) by boosting with recombinant HIV envelope. Poster, 6th International Conference on AIDS, San Francisco, California, June 20-24, 1990;1:203 [Th.A.333].
gen	Detrick B, Bradac J, Schultz AM, Koff WC, Mathieson BJ. An epitope map for HIV-1. Publication Abstract, 6th International Conference on AIDS, San Francisco, California, June 20-24, 1990;2:327 [1053].
003 core	Dolin R, Graham B, Greenberg S, Tacket C, Belshe R, Clements ML, Fernie B, Montefiori D, Stablein D, Smith G, Lawrence D, Koff W, AIDS Vaccine Clinical Trials Network. Serum antibody responses following administration of a fourth dose of HIV-1 recombinant gp-160 vaccine to normal volunteers. Presentation, 3rd Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Clearwater Beach, Florida, October 1-5, 1990.
003 core	Dolin R, Graham B, Greenberg S, Tacket C, Belshe R, Clements ML, Fernie B, Stablein D, Smith G, Lawrence D, Koff W. Serum antibody responses following administration of a fourth dose of HIV-1 recombinant gp-160 vaccine to normal volunteers. Publication Abstract, 6th International Conference on AIDS, San Francisco, California, June 20-24, 1990;2:329 [1061].
003	Ellerbeck E, Viscidi R, Midthun K, Clements ML, Smith G, NIAID AIDS Vaccine Clinical Trials Network. Characteristics of gp160 EIA antibody response of adults to a fourth dose of rgp160 vaccine. Publication Abstract, 6th International Conference on AIDS, San Francisco, California, June 20-24, 1990;2:326 [1049].
gen	Glass MW, Schultz AM, Mathieson BJ, Lawrence D, Wescott S, Koff WC. Conference Report. Second Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, 15-18 October 1989; Fort Lauderdale, Florida USA. Vaccine. 1990;8:413-414.
002 anc	Gorse G, Belshe R, NIAID AIDS Vaccine Clinical Trials Network. Lymphocyte proliferative responses following immunization with HIV vaccines. Poster, 8th International Congress of Virology, Berlin, Germany, August 1990 [P38-5].
002	Graham B, Belshe R, Midthun K, Dolin R, Fernie B, Stablein D, Wright P, Koff W, NIAID AIDS Vaccine Clinical Trials Network. HIV gp160 recombinant vaccinia in vaccinia-naive adults. Publication Abstract, 6th International Conference on AIDS, San Francisco, California, June 20-24, 1990;2:346 [1131].
002	Graham BS, Belshe R, Clements ML, Dolin R, Fernie B, Stablein D, Wright P, Koff W, NIAID AIDS Vaccine Clinical Trials Network. HIV gp160 recombinant vaccinia in vaccine-naive adults. Poster, 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia, October 21-24, 1990 [549].
002	Graham BS, Belshe R, Clements ML, Dolin R, Fernie B, Stablein D, Wright P, Koff W, NIAID AIDS Vaccine Clinical Trials Network. HIV gp160 recombinant vaccinia vaccination of vaccinia-naive adults. Presentation, 3rd Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Clearwater Beach, Florida, October 1-5, 1990.
gen	Karzon DT, Lawrence DN, Wescott SL, Koff WC. Guidelines for selecting candidate AIDS vaccines for Phase I and II clinical testing. Presentation, 6th International Conference on AIDS, San Francisco, California, June 20-24, 1990.
003	Keay S, Murphy J, Tacket CO. Anti-CD4 antibodies in volunteers immunized with rgp160 associated with rapid decline in anti-rgp160. Poster, 6th International Conference on AIDS, San Francisco, California, June 20-24, 1990;3:160 [S.A.314].
002 anc	Keefer MC, Bonnez W, Roberts NJ Jr, Lambert J, Dolin R, Reichman R. HIV-1 rgp160-specific cellular immune responses by recipients of a live vaccinia-rgp160 vaccine. Publication Abstract, 6th International Conference on AIDS, San Francisco, California, June 20-24, 1990;2:326 [1051].
002 anc	Keefer MC, Roberts NJ Jr, Bonnez W, Lambert J, Dolin R, Reichman R. HIV-1 rgp160-specific cellular immune responses by recipients of a live vaccinia-rgp160 vaccine. Poster, 3rd Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Clearwater Beach, Florida, October 1-5, 1990 [49].
gen	Koff WC, Schultz AM, Mathieson BJ, Detrick B, Glass MJ, Wescott SL, Lawrence DN. AIDS vaccine development: scientific and public policy challenges for the 1990's. Poster, 6th International Conference on AIDS, San Francisco, California, June 20-24, 1990;1:202 [Th.A.330].
nhp	Levinson MA, Warren JT, Smith CM, Schultz AM. Development of a distributed data system to support SIV vaccine trials. Poster, 3rd Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Clearwater Beach, Florida, October 1-5, 1990 [56].
gen	Mathieson B. Perinatal intervention: immunological truth and consequences. Presentation, 3rd Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Clearwater Beach, Florida, October 1-5, 1990.
003	Montefiori DC, Graham B, Robinson WE Jr, Wright P, NIAID AIDS Vaccine Clinical Trials Network. HIV neutralizing and enhancing antibody responses to MicroGeneSys rgp160 vaccine in humans. Publication Abstract, 6th International AIDS Conference, San Francisco, California, June 20-24, 1990;2:340 [1107].
002, 003 anc	Mosier DE, Gulizia RJ, MacIsaac P, Spector SA, Spector DH, Baird SM, Shearer GM, Tacket C, Mathieson B, Koup R, Sullivan J, Corey L, Greenberg P. Evaluation of HIV immunity in the hu-PBL-SCID mouse model. Presentation, 3rd Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Clearwater Beach, Florida, October 1-5, 1990.
gen	Schultz AM, Koff WC, Lawrence DN. Conference Report. Workshop on HIV Inactivated Vaccines, 9 February 1990, Bethesda, Maryland USA. Vaccine. 1990;8:516-517.
003 anc	Siliciano R, Orentas R, Hildreth J, Obah E, Gebo K, Clements ML, Ellerbeck E. A recombinant HIV-1 envelope protein vaccine induces CD4+ human cytolytic T lymphocytes (CTL) active against HIV-1-infected cells. Presentation, 6th International Conference on AIDS, San Francisco, California, June 20-24, 1990;3:115 [S.A.79].
gen	Stein R. Legal issues in AIDS vaccine development. Presentation, 3rd Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Clearwater Beach, Florida, October 1-5, 1990.
nhp	Warren JT, Levinson MA, Smith CM, Koff WC. Activity and resources tracking system for AIDS vaccine research: an essential program planning tool. Poster, 3rd Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Clearwater Beach, Florida, October 1-5, 1990 [55].

Manuscripts

gen	Clements ML. AIDS vaccines. In: Mandell GL, Douglas RG, Bennett JE, eds. Principles and Practice of Infectious Diseases. New York, NY: Churchill-Livingstone; 1989:1112-1121.
gen	Garrison L, Clements ML. Development of new vaccines for AIDS. Compr Ther. 1989;15:60-68.
gen	Muul LM, Glass MJ, Wescott SL, Burkhardt AL, Koff WC, Strober WG. Meeting Summary. The role of mucosal immunity in development of an acquired immunodeficiency syndrome (AIDS) vaccine: workshop summary. Reg Immunol. 1989;2:188-192.

OUTSIDE COLLABORATIONS

gen	Berkower I, Smith GE, Giri C, Murphy D. Human immunodeficiency virus 1: predominance of a group-specific neutralizing epitope that persists despite genetic variation. J Exp Med. 1989;170:1681-1695.

Abstracts/Presentations

003 anc	Archibald D, Amrheim C, Sun D, Tacket C. Salivary antibodies to HIV antigens in an AIDS vaccine trial. Poster, 5th International Conference on AIDS, Montreal, Canada, June 4-9, 1989;548 [M.C.P.37].
gen	Belshe R, Schindzielorz A, NIAID AIDS Vaccine Program. Occurrence of indeterminant Western Blot (IWB) tests and lack of transmission of IWB in persons at low risk for HIV infection, Huntington, WV, USA, 1986-1988. Poster, 5th International Conference on AIDS, Montreal, Canada, June 4-9, 1989;155 [Th.A.P.88].
003	Dolin R, Graham B, Greenberg S, Tackett C, Belshe R, Clements M, Fernie B, Stablein D, Smith G, Koff W. Safety and immunogenicity of HIV-1 recombinant gp160 vaccine candidate in normal volunteers. Presentation, 5th International Conference on AIDS, Montreal, Canada, June 4-9, 1989;538 [Th.C.O.33].
003 core	Dolin R, Graham B, Tackett C, Belshe R, Clements ML, Fernie B, Stablein D, Smith G, Koff W, NIAID AIDS Vaccine Clinical Trials Network. Safety and immunogenicity of an HIV-1 recombinant gp160 candidate vaccine in humans. Slide Presentation, 2nd Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Fort Lauderdale, Florida, October 15-18, 1989.
gen	Ellerbeck E, Viscidi R, Clements ML, Midthun K, Clayman B, NIAID AIDS Vaccine Evaluation Group. Kinetics, magnitude and duration of antibody responses in HIV-1 rgp160 vaccinees. Poster, 2nd Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Fort Lauderdale, Florida, October 15-18, 1989.
gen anc	Fenger TW, Seaman T, Belshe R, NIAID AIDS Vaccine Program. Plaque reduction assay to detect HIV neutralizing antibodies in sera from human vaccinees. Poster, 5th International Conference on AIDS, Montreal, Canada, June 4-9, 1989;545 [M.C.P.23].
003 core	Garrison L, Midthun K, Clayman B, Smith G, Viscidi R, NIAID AIDS Vaccine Evaluation Group. Kinetics, magnitude and duration of antibody responses in HIV-1 rgp160 vaccinees. Poster, 5th International Conference on AIDS, Montreal, Canada, June 4-9, 1989;543 [M.C.P.12].
mult	Garrison L, Midthun K, Fernie B, Farzadegan H, Clements ML, NIAID AIDS Vaccine Evaluation Group. Western Blots: indeterminate results and lot-to-lot variability in adults at low risk for HIV-1 infection. Poster, 5th International Conference on AIDS, Montreal, Canada, June 4-9, 1989;307 [T.B.P.123].
003 anc	Gorse G, Newman F, Belshe RB, NIAID AIDS Vaccine Program. Antibody dependent cellular cytotoxicity (ADCC) following vaccination with a recombinant HIV-1 gp160 vaccine. Presentation, 5th International Conference on AIDS, Montreal, Canada, June 4-9, 1989;538 [Th.C.O.32].
002	Graham B, Rowland J. Kinetics of HIV infected cell-to-cell fusion. Published Abstract, 5th International Conference on AIDS, Montreal, Canada, June 4-9, 1989;678 [C.720].
003	Graham B, Rowland J, Robinson E, Montefiori D, Mitchell W, Wright P, NIAID Vaccine Evaluation Group. Functional antibody response in persons immunized with baculovirus-derived gp160. Poster, 5th International Conference on AIDS, Montreal, Canada, June 4-9, 1989;545 [M.C.P.19].
gen	Graham B, Wetherall N. A mouse model for investigating HIV-1 replication. Poster, 5th International Conference on AIDS, Montreal, Canada, June 4-9, 1989;615 [W.C.P.144].
003 anc	Keefer MC, Bonnez W, Roberts NJ Jr, Dolin R, Reichman RC. HIV-1 gp160-specific lymphocyte proliferative responses of peripheral blood mononuclear leukocytes (PBML) from HIV-1 vaccine recipients. Poster, 2nd Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Fort Lauderdale, Florida, October 15-18, 1989.
003 anc	Keefer MC, Bonnez W, Roberts NJ Jr, Dolin R, Reichman RC. HIV-1 recombinant gp160 vaccine recipients demonstrate gp160-specific lymphocyte proliferation prior to Western Blot reactivity. Poster, 5th International Conference on AIDS, Montreal, Canada, June 4-9, 1989;543 [M.C.P.8].
gen	Koff WC, Wescott SL, Novak J, Stablein D, Fernie B, Gerin J (NIAID AIDS Vaccine Evaluation Group). Clinical evaluation of experimental AIDS vaccines. Poster, 5th International Conference on AIDS, Montreal, Canada, June 4-9, 1989;542 [M.C.P.3].
gen	Kotloff K, Tacket C, Bridwell M, Cowan J, Wasserman S, Quinn T. Prevalence of HIV-1 infection among college students. Poster, 5th International Conference on AIDS, Montreal, Canada, June 4-9, 1989;101 [T.A.P.16].
003	Midthun K, Garrison L, Gershman K, Clements ML, Smith G, Adler W. Cellular immunity in HIV-1 rgp160 vaccinees. Poster, 5th International Conference on AIDS, Montreal, Canada, June 4-9, 1989;544 [M.C.P.14].
gen	Nord J, Ma P, Tacket CO, Dijohn D, Tzipori S, Sahner D, Shieb G. Treatment of AIDS associated cryptosporidiosis with hyper-immune colostrum from cows vaccinated with Cryptosporidium. Publication Abstract, 5th International Conference on AIDS, Montreal, Canada, June 4-9, 1989;656 [C.586].
003 anc	Reuben J, Liang L, Li S, Greenberg S, Smith G, Couch R. In vitro B cell differentiation in normals, rgp160 vaccinated volunteers, and HIV+ subjects. Poster, 5th International Conference on AIDS, Montreal, Canada, June 4-9, 1989;433 [Th.B.P.104].
anc	Schindzielorz A, Belshe R, Read J, Mufson M. Absence of HIV-1 and HIV-2 infection in African tribes, 1968-72. Publication Abstract, 5th International Conference on AIDS, Montreal, Canada, June 4-9, 1989;1025 [G.519].
gen	Schultz AM, Glass M. SIV vaccine development surveillance. Poster, 5th International Conference on AIDS, Montreal, Canada, June 4-9, 1989;546 [M.C.P.27].
gen	Spriggs DR, Ellenberg SS. Study design issues in SIV vaccine trials. Poster, 5th International Conference on AIDS, Montreal, Canada, June 4-9, 1989;549 [M.C.P.45].
gen	Stablein DM. Challenges of HIV vaccine development. Presentation, Biometrics ENAR Meeting, Lexington, Kentucky, March 20, 1989.
gen	Wagner L, Wallston K, Hensman BJ, Graham BS, Schaffner W, Copello G. AIDS vaccine volunteers: A motivational and psychosocial profile. Poster, International Conference on AIDS Education, Nashville, Tennessee, September 1989.
gen, 003 anc	Westblom TU, Belshe RB, Gorse GJ, Anderson EL, Berry CF, NIAID AIDS Vaccine Program. Demographic characteristics and frequency of exclusionary criteria in a population volunteering for HIV immunization. Poster, 5th International Conference on AIDS, Montreal, Canada, June 4-9, 1989;547 [M.C.P.32].
002	Wright P. HIV-1 gp160 expressed by vaccinia - Preliminary results of safety and immunogenicity of recombinant vaccinia in naive individuals studied by the NIAID AIDS Vaccine Clinical Trials Network. Presentation, 2nd Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Fort Lauderdale, Florida, October 15-18, 1989.

OUTSIDE COLLABORATIONS

gen	Clouse KA, Washington IR, Fernie B, Ostrove JM, Fauci AS. Viral antigen stimulation of the secretion of human monokines capable of regulating HIV-1 expression. Poster, 5th International Conference on AIDS, Montreal, Canada, June 4-9, 1989;609 [W.C.P.105].

Abstracts/Presentations

gen	Rowland JM, Montefiori DC, Robinson WE, Graham BS, Modliszewski A, Mitchell WM. Anti-fusion activity of serum from HIV infected persons. Slide Presentation, 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, California, October 23-26, 1988 [73].